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Abstract	  	  It	  is	  of	  the	  utmost	  importance	  to	  have	  control	  over	  the	  stereochemistry	  of	  the	  molecules	  that	  we	  synthesise,	  be	  they	  for	  use	  as	  drugs,	  materials	  or	  substrates	  for	  further	  chemical	  transformation,	  etc.	  In	  recent	  years,	  organocatalysis	  has	  been	  presented	  as	  a	  previously	  unexploited	  route	  for	  this	  purpose	  that	  is	  both	  highly	  tuneable	  to	  specific	  requirements	  and	  avoids	  totally	  the	  use	  of	  transition	  metals,	  which	  can	  be	  costly	  or	  can	  contaminate.	  The	  use	  of	  organocatalysts	  to	  catalyse	  asymmetric	  aziridination	  reactions	  is	  a	  relatively	  new	   concept.	   In	   recent	   years	   several	   examples	   of	   organocatalytic	   enantioselective	  aziridination	   reactions	   have	   now	  been	   successfully	   developed.	   Among	   these	   examples	  are	  reactions	  that	  are	  catalysed	  by	  quaternary	  salts	  of	  cinchona	  alkaloids,	  which	  are	  able	  in	  many	  cases	  to	  transfer	  chirality	  to	  the	  aziridine	  heterocycle.	  	  Recent	   work	   within	   the	   Bew	   group	   has	   demonstrated	   that	   racemic	   aziridination	  reactions	  can	  be	  catalysed	  using	  fluoronium	  sources.	  Herein	  we	  investigate	  the	  potential	  of	   N-­‐fluoro	   cinchona	   salts	   as	   a	   new	   method	   of	   enantioselectively	   catalysing	  aziridinations	   using	   the	   fluoronium	   ion.	   The	   synthesis	   of	   catalysts	   by	  etherification/esterification	   and	   fluorination	   and	   their	   application	   in	   catalysing	  aziridinations	  will	  be	  discussed.	  	  During	  the	  course	  of	  the	  fluoronium	  investigation,	  we	  also	  became	  interested	  in	  the	  use	  of	   ionic	   liquids	   as	   organocatalysts	   for	   the	   same	   class	   of	   reactions.	   Symmetrical	  imidazolium-­‐based	   ionic	   liquids	   have	   been	   shown	   to	   simultaneously	   solvate	   and	  catalyse	   racemic	   aziridine	   formation	   and	   are	   also	   recyclable	   and	   remove	   the	   need	   for	  solvent.	   There	   are	   now	   several	   reported	   chiral	   ionic	   liquids	   built	   around	   this	   key	  imidazolium	   functionality.	   Therefore	   we	   will	   also	   discuss	   our	   strategy	   to	   control	   the	  absolute	   stereochemistry	   of	   this	   method	   by	   using	   chiral	   ionic	   liquids	   containing	   the	  imidazolium	  motif.	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1 -­‐	  	  Introduction	  
1.1 	  -­‐	  A	  Brief	  History	  of	  Asymmetric	  Catalysis	  and	  Organocatalysis	  Methods	   of	   inducing	   enantiopurity	   in	   chiral	   reaction	  products	   have	   been	   the	   focus	   of	  research	   for	   many	   years.	   It	   is	   of	   the	   utmost	   importance	   to	   have	   control	   over	   the	  stereochemistry	  of	  the	  molecules	  that	  we	  synthesise,	  be	  they	  for	  use	  as	  drugs,	  materials	  or	  substrates	  for	  further	  chemical	  transformation,	  etc.	  An	  increasingly	  large	  proportion	  of	  these	  methods	  now	  also	  take	  carefully	  into	  consideration	  the	  “atom	  economy”	  of	  such	  reactions.1	   	   Asymmetric	   catalysts	   cater	   well	   to	   this	   desire	   for	   economy	   by	   efficiently	  passing	  chirality	  onto	  the	  reaction	  product.	  This	  allows	  for	  the	  production	  of	  many	  more	  molecules	   of	   valuable,	   asymmetric	   product	   than	   the	   loading	   of	   the	   catalyst	   itself	   and	  reduces	   or	   removes	   entirely	   the	   need	   to	   use	   stoichiometric	   quantities	   of	   chiral	  auxiliaries.2	  Until	   very	   recently	   asymmetric	   catalysis	   has	   been	   dominated	   by	   transition	   metal	  complex	   and	   enzyme	   catalysts.	   Transition	   metal	   catalysts	   offer	   a	   high	   degree	   of	  customisability,	   meaning	   that	   they	   can	   be	   tailored	   and	   refined	   to	   produce	   high	  enantioselectivity	  and	  catalytic	  activity.	  The	  2001	  Nobel	  Prize	  in	  Chemistry	  to	  Knowles	  and	   Noyori	   ‘‘for	   their	   work	   on	   chirally	   catalysed	   hydrogenation	   reactions’’,	   and	   to	  Sharpless	   ‘‘for	   his	   work	   on	   chirally	   catalysed	   oxidation	   reactions”	   (See	   Scheme	   1.),	  demonstrating	  just	  how	  important	  this	  class	  of	  reactions	  is	  considered	  to	  be	  in	  modern	  times.3a-­‐c	  
	  










































However,	   transition	   metal	   catalysts	   are	   not	   without	   their	   disadvantages.	   Transition	  metal	  catalysts	  can	  often	  be	  highly	  prone	  to	  degradation	  upon	  exposure	  to	  moisture	  or	  oxygen	   or	   ambient	   temperatures,	   making	   them	   difficult	   and	   expensive	   to	   handle,	   in	  addition	   to	   transition	  metals	   themselves	   often	   being	   expensive.	   The	   use	   of	   transition	  metals	  is	  seen	  as	  undesirable	  undesirable	  in	  processes	  such	  as	  drug	  manufacture,	  which	  do	  not	  tolerate	  metal	  contamination.	  Enzyme	   catalysis	   or	   “biocatalysis“	   is	   the	   use	   of	   enzymes	   to	   facilitate	   chemical	  transformations	  in	  synthetic	  chemistry.	  Biocatalysts	  are	  highly	  efficient,	  always	  require	  mild	  reaction	  conditions	  and	  also	  have	  the	  advantage	  of	  being	  extremely	  regiospecific	  as	  the	  active	   sites	  of	   these	  molecules	  are	   tailored	   in	   size	  and	  shape	   to	   recognise	   specific	  region	  of	  the	  substrate.	  An	  example	  of	  the	  synthetic	  application	  of	  biocatalysts	  would	  be	  Smallridge	  et	  al.’s	  use	  of	  yeast	  to	  reduce	  ethyl	  acetoacetate,	  3	  to	  the	  acetoalcohol,	  4	  (See	  
Scheme	  2).	  4	  
	  










addition	   of	   hydrogen	   cyanide	   to	   benzaldehyde	   and	   produced	   an	   enantio-­‐enriched	  reaction	  product.	  Although	  the	  enantiomeric	  excesses	  generated	  in	  these	  reactions	  were	  no	  higher	  than	  10%,	  at	  that	  time	  the	  use	  of	  small	  organic	  catalytic	  molecules	  to	  induce	  any	  asymmetry	  in	  a	  reaction	  product	  was	  unprecedented.	  
	   	  
Figure	  1.	  The	  asymmetric	  alkaloid	  catalysts	  5	  &	  6	  employed	  by	  Bredig	  and	  Fiske	  in	  1912.	  
	   	  








































Scheme	  4.	  Pracejus	  et	  al.’s	  use	  of	  10	  to	  mediate	  the	  reaction	  between	  ketene,	  9	  and	  methanol.	  Despite	  the	  discovery	  of	  asymmetric	  organocatalysis	  occurring	  in	  the	  early	  20th	  century,	  further	   advances	   in	   enantioselectivity	   of	   organocatalysis	   were	   not	   made	   until	   1971	  when	   Hajos	   and	   Parish	   reported	   the	   (S)-­‐(-­‐)-­‐proline	   catalysed	   asymmetric	  intramolecular	   aldol	   cyclisation	   of	   the	   Wieland-­‐Miescher	   ketone	   to	   form	   a	   key	  intermediate	  in	  steroid	  synthesis	  in	  93%	  enantiomeric	  excess7	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Scheme	  6.	  General	  Hajos-­‐Parrish-­‐Eder-­‐Sauer-­‐Wiecher	  Reaction	  scheme	  
1.1.1 -­‐	  Covalent	  Organocatalysis	  In	  order	  to	  investigate	  new	  organocatalysts,	  one	  first	  needs	  to	  understand	  the	  principles	  that	  underpin	  organocatalysis	  as	  a	  whole.	   It	   is	   true	   that	  despite	   the	  enormous	  growth	  and	  interest	  in	  the	  field	  over	  recent	  years,	  that	  organocatalysts	  can	  generally	  be	  placed	  in	  one	  of	  two	  simply	  defined	  groups:	  “covalent”	  and	  “non-­‐covalent”.	  Covalent	  organocatalysts	   form	  covalent	   adducts	  with	   the	   substrates	   and	   the	   resultant	  adducts	  are	  activated	  towards	  a	  desired	  reaction.	  In	  general,	  the	  formation	  of	  covalent	  substrate–catalyst	  adducts	  proceed	  by	  single-­‐step	  Lewis-­‐acid–Lewis-­‐base	  addition	  or	  by	  multi-­‐step	  reactions	  such	  as	  the	  formation	  of	  enamines	  from	  aldehydes	  and	  secondary	  amines	  as	  discussed	  in	  the	  Hajos-­‐Parrish-­‐Eder-­‐Sauer-­‐Wiecher	  example.	  (Schemes	  5	  and	  







































Scheme	  7.	  Macmillan	  et	  al.’s	  strategy	  for	  the	  asymmetric	  imidazolidinone	  catalysed	  Diels-­‐Alder	  reaction	  mediated	  by	  17.	  An	  example	  of	  a	  more	  simple	  Lewis-­‐acid–Lewis-­‐base	  addition	  mechanism	  would	  be	  the	  phosphine-­‐catalysed	  acyl	   transfer	   reactions.	  Vedejs	  et	  al.	   reported	  an	  enantioselective	  acylations	   catalysed	   by	   the	   chiral	   phosphine,	   21	   (See	   Scheme	   8).10	   21	   reacts	  nucleophilically	   to	   form	   a	   chiral	   cationic	   adduct	  with	   one	   acyl	   unit	   of	   an	   appropriate	  anhydride.	  (20	  in	  the	  case	  of	  the	  optimal	  example).	  The	  adduct	  recognises	  enantiomers	  of	  secondary	  alcohols,	  in	  this	  case	  2,2,-­‐dimethyl-­‐1-­‐phenylpropan-­‐1-­‐ol,	  19	  and	  is	  able	  to	  acylate	   the	   R-­‐enantiomer	   selectively,	   generating	   an	   81%	   enantiomeric	   excess	   in	   this	  example.	  
	  
	  














































1.1.2 -­‐	  Non-­‐covalent	  Organocatalysis	  In	  many	  cases,	  non-­‐covalent	  organocatalysts	  rely	  on	  the	   formation	  of	  hydrogen	  bonds	  and/or	   protonation/deprotonation	   between	   the	   catalyst	   and	   the	   substrate	  molecules.	  One	   such	   example	  would	   be	   Jacobsen’s	   thiourea	   catalyst	   for	   the	   asymmetric	   Strecker	  reaction.12	   The	   extensively	   functionalised	   chiral	   thiourea	   24	   forms	   hydrogen	   bonds	  with	  the	  lone	  pair	  of	  the	  imine,	  N-­‐allylbenzaldimine	  in	  this	  case,	  and	  activates	  it	  towards	  nucleophilic	  addition	  of	  cyanide,	  giving	  the	  (S)	  enantiomer	  of	  the	  addition	  product	  in	  an	  impressive	  95	  %enantiomeric	  excess	  (See	  Scheme	  9).	  
	  


































to	   cross	   the	   phase	   boundary	   into	   a	   toluene/chloroform	   mixture,	   where	   the	  deprotonated	   indanone,	   26	   reacts	   readily	   with	   chloroform	   to	   give	   the	   β-­‐methylated	  ketone,	  28	  in	  an	  excellent	  95%	  yield	  and	  92%	  enatiomeric	  excess	  (See	  Scheme	  10).	  
	  
























Scheme	  11.	  Terada	  et	  al.’s	  use	  of	  chiral	  phosphoric	  acid,	  30,	  as	  a	  highly	  efficient	  enantioselective	  organocatalyst	  for	  Mannich	  type	  reactions.	  
1.2 	  -­‐	  Aziridines	  Aziridines	   are	   a	   family	   of	   molecules	   defined	   by	   a	   three	   membered,	   saturated	  heterocyclic	  motif	   containing	  a	   single	  nitrogen	  atom,	  and	  are	  widely	   considered	   to	  be	  analogues	  or	  “cousins”	  of	  the	  oxygen-­‐containing	  epoxides	  due	  to	  their	  similar	  structure,	  reactivity	  and	  stereochemistry.15	  The	  internal	  bond	  angles	  within	  an	  aziridine	  molecule	  can	  be	  considered	  to	  be	  approximately	  60°,	  which	  differs	  considerably	  to	  the	  minimum	  energy	  bond	  angle	  of	  109.5°	   for	  Sp3	  hybridised	  centres.	  Therefore,	   the	  aziridine	  motif	  incorporates	  high	  strain	  energies	  (typically	  -­‐1)	  and	  the	  result	  can	  be	  considered	  to	  be	  a	  “spring-­‐loaded”	  structure.	  
	   	  
Figure	  2.	  The	  core	  structure	  of	  aziridine	  molecules.	  	  It	   is	   this	   structural	   feature	   that	   makes	   aziridines	   highly	   amenable	   to	   ring-­‐opening	  reactions	  via	  nucleophilic	  attack	  or	  cycloaddition	  reactions,	  both	  of	  which	  result	  in	  the	  cleavage	  of	  the	  C-­‐N	  bond	  and	  are	  driven	  by	  the	  relieving	  the	  molecule	  of	   its	  high	  ring-­‐




























strain.	   In	   addition	   to	   this	   ease	   of	   ring-­‐opening,	   aziridine	   molecules	   incorporate	   two	  adjacent	   stereocentres,	   which	   directly	   affect	   the	   stereochemistry	   of	   ring-­‐opened	  products,	  making	  aziridines	  tremendously	  appealing	  reactive	  intermediates	  in	  synthetic	  chemistry	   (See	  Scheme	  12).	  Aziridines	  allow	   for	   the	   selective	  1,2-­‐functionalistion	  with	  respect	  to	  the	  nitrogen	  atom	  and	  therefore	  represent	  to	  synthetic	  chemists	  a	  convenient	  method	  of	  accessing	  many	  nitrogen-­‐containing	  molecules	  of	  interest.16	  	  
	  
Scheme	  12.	  	  An	  illustration	  of	  an	  aziridine	  undergoing	  nucleophilic	  ring-­‐openning	  	  It	   is	   of	   little	   surprise	   then	   that	   aziridines	   have	   been	   attracting	   much	   attention	   from	  chemists	   for	  many	   years	   because	   of	   they	   provide	   an	   easy	   route	   to	   pharmacologically	  and	  biologically	  active	  compounds.	  Aziridines	  have	  many	  applications	  as	  chiral	  building	  blocks	  for	  the	  construction	  of	  various	  chiral	  nitrogen	  compounds	  such	  as	  chiral	  amines,	  amino	  acids,	  β-­‐aminosulfonic	  acids,	  amino	  alcohols,	  alkaloids	  and	  β-­‐lactam	  antibiotics.	  By	   ring	   opening	   the	   chiral	   aziridine,	   32,	   and	   the	   subsesequently	   reducing	   and	  deprotecting	  the	  resultant	  product,	  Wulff’s	  synthesis	  of	  (-­‐)-­‐Chloramphenicol	  is	  a	  prime	  example	   of	   how	   biologically	   active	   nitrogen-­‐containing	   molecules	   can	   be	   easily	   and	  access	  from	  chiral	  aziridine	  starting	  materials	  (See	  Scheme	  13).17	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Fig	  3.	  Examples	  of	  biologically	  active	  aziridines-­‐containing	  molecules.	  Many	  aziridines	  have	  the	  ability	  to	  act	  as	  DNA	  cross-­‐linking	  agents	  via	  nucleophilic	  ring	  opening	   of	   the	   aziridine	   moiety.	   Structure–activity	   relationships	   have	   identified	   the	  aziridine	   ring	   as	   being	   essential	   for	   the	   anti-­‐tumour	   activity	   and	   various	   anti-­‐tumour	  agents	  related	  to	  mitosanes	  and	  mitomycins	  have	  been	  synthesised	  and	  demonstrated	  to	   possess	   activity	   against	   a	   variety	   of	   cancers.	   A	   number	   of	   other	   synthetic	   chiral	  aziridines	   are	   shown	   to	   exhibit	   other	   useful	   biological	   properties	   such	   as	   enzyme-­‐inhibitory	  activities.	  
	   	  
Fig	  4.	  A	  molecule	  of	  37	  cross-­‐linking	  DNA	  strands	  by	  binding	  to	  two	  guanine	  residues	  


































































1.2.1 -­‐	  Syntheses	  of	  Asymmetric	  Aziridines	  	  The	  first	  synthesis	  of	  an	  aziridine	  molecule	  was	  reported	  by	  Gabriel	  in	  1888	  and	  since	  then	  a	  multitude	  of	  different	  methods	  for	  the	  synthesis	  of	  this	  class	  of	  compound	  have	  been	  reported	  and	  continue	  to	  increase	  in	  number	  to	  the	  present	  day.21	  Chiral	  aziridines	  can	  be	  accessed	  using	  asymmetric	  catalysis	  or	  from	  chiral	  auxiliaries,	  in	  the	  interest	  of	  relevance	  to	  the	  current	  study	  the	  later	  will	  not	  be	  discussed	  any	  further	  here.	  Catalytic	  methods	   for	   the	   formation	   of	   chiral	   aziridines	   fall	   generally	   within,	   but	   are	   not	  restricted	  to,	  two	  sub-­‐types:	  Addition	  of	  nitrogen	  to	  alkenes	  and	  the	  addition	  of	  carbon	  to	  imines.	  Evans	  et	  al.	  reported	  one	  of	  the	  first	  asymmetrically	  catalysed	  syntheses	  of	  an	  aziridine	  molecule	   in	   1991	  using	   chiral	  bis(oxazoline)	   copper	   catalysts,	   producing	   a	  mixture	   of	  the	  two	  possible	  diastereomers,	  both	  in	  moderate	  enantiomeric	  excess.22	  In	  1993	  Using	  a	   chiral	   ligand,	  40	   in	   combination	  with	   copper(I)trifluoromethanesulfonate	   the	   same	  authors	   added	   nitrogen	   across	   achiral	   olefin	   substrates	   using	   [N-­‐(p-­‐toluenesulfonyl)imino]phenyliodinane	   (PhI=NTs)	   as	   a	   nitrene	   source.23	   This	   revised	  method	   produce	   the	   desired	   aziridines	   exclusively	   in	   the	   trans-­‐orientation	   and	   in	  exceptional	  optimal	  97%	  enatiomeric	  excess	  (See	  Scheme	  14).	  	  
	  
Scheme	  14.	  An	  example	  of	  Evans’s	  pioneering	  asymmetrically	  copper-­‐catalysed	  aziridinations.	  It	   is	   true	   that	   the	  majority	   of	   reported	  metal-­‐catalysed	   asymmetric	   aziridinations	   are	  concerning	   the	   transfer	   of	   nitrogen	   across	   alkenes.	   However,	   there	   are	   examples	   of	  formation	   of	   chiral	   aziridines	   upon	   transition	   metal-­‐catalysed	   reaction	   of	   diazo	  compounds	   with	   imines	   and	   is	   well	   established.	   In	   particular,	   the	   reaction	   of	   ethyl	  diazoacetate	   with	   imines	   mediated	   by	   a	   Lewis	   acid	   is	   normally	   selective	   for	   the	  formation	   of	   the	   cis-­‐aziridine.	   A	   good	   example	   of	   this	   class	   of	   asymmetric	   metal	  catalysed	   reactions	  would	   be	   a	   study	   carried	   out	   by	  Hossain	  et	   al.,	  who	   employed	   an	  
PhI NTs
5 mol% 40













Iron(II)-­‐pybox	   catalyst,	  44,	   in	   combination	   with	   silverhexafluoroantimonate(V)	   as	   an	  initiator	  to	  mediate	  an	  asymmetric	  aza-­‐Darzens	  reaction	  between	  substituted	  aldimines	  and	   ethyl	   diazoacetate,	   affording	   mainly	   cis-­‐aziridines	   in	   up	   to	   a	   49%	   enantiomeric	  excess	  (See	  Scheme	  15).	  	  
	  
Scheme	  15.	  Hossain	  et	  al.’s	  use	  of	  an	  Iron(II)-­‐pybox	  catalyst,	  44	  for	  in	  combination	  with	  silverhexafluoroantimonate(V)	  for	  the	  asymmetric	  aza-­‐Darzens	  reaction.	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Scheme	  16.	  Fioravanti,	  Pellacani	  and	  Tardella’s	  use	  of	  quaternary	  cinchona	  alkaloid	  salt,	  38,	  as	  a	  catalyst	  to	  mediate	  a	  Michael	  initiated	  asymmetric	  aziridination.	  In	  2007,	  Wulff	  et	  al.	  reported	  the	  most	  successful	  and	  versatile	  procedure	  to	  date	  for	  the	  asymmetric	   organocatalysed	   aza-­‐Darzens	   reaction	  of	  N-­‐dianisylmethyl	   aldimines	  with	  ethyl	   diazoacetate	  mediated	   by	   (S)-­‐VANOL	   and	   (S)-­‐VAPOL	   based	   boric	   acid	   catalysts,	  achieving	   high	   yields	   and	   up	   to	   a	   97%	  enatiomeric	   excess.26	   Two	   subsequent	   studies	  were	   carried	   out	   by	   the	   same	   author	   using	  N-­‐biphenylmethyl	   aldimine	   and	  N-­‐3,5-­‐di-­‐tert-­‐butyldianisylmethyl	   aldimine	   substrates	   with	   diazoacetate	   respectively.27,28	   This	  broughtthe	   total	  number	  of	   reported	  examples	   for	   these	   (S)-­‐VANOL/(S)-­‐VAPOL	  based	  organocatalytic	  reactions	  to	  60,	  all	  of	  which	  exhibited	  high	  yields	  and	  between	  the	  range	  of	  75-­‐97%	  enatiomeric	  excess	  (See	  Scheme	  17),	  demonstrating	  the	  excellent	  versatility	  of	  this	  catalyst	  system.	  	  	  
	  
Scheme	  17.	  An	  optimum	  example	  taken	  from	  Wulff’s	  work	  towards	  asymmetric	  aziridination	  mediated	  by	  (S)-­‐VANOL-­‐derived,	  50,	  or	  (S)-­‐VAPOL-­‐derived,	  51.	  
1.3 	  -­‐	  Aims	  of	  Research	  
1.3.1 	  -­‐	   Fluoronium	  Organocatalysts	   for	   the	  Asymmetric	   aza-­‐Darzens	  



























51 = 96% e.e.
49 52
15	  	  
trifluoromethanesulfonate	   as	   a	   Brønsted	   type	   acid	   catalyst	   (See	   Scheme	   18).29	  Noteworthy	  features	  of	  this	  reaction	  are	  that	  it	  is	  extremely	  mild	  in	  comparison	  with	  the	  majority	  of	  acid	  catalysts	  and	  that	  it	  is	  exceptionally	  selective	  towards	  the	  formation	  of	  
cis-­‐aziridines,	   producing	   no	   observable	   trans-­‐isomer	   in	   many	   cases.	   Much	   work	   has	  been	   carried	   out	   within	   the	   Bew	   group	   since	   this	   publication	   to	   develop	   other	   acid	  catalysts	  that	  exhibit	  control	  over	  the	  absolute	  stereochemistry	  of	  the	  aziridine	  product,	  with	  very	  encouraging	  results	  that	  will	  no	  doubt	  find	  their	  way	  into	  the	  public	  domain	  in	  the	  near	  future.	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Brønsted	   acids,	   a	   hypothesis	   that	   was	   confirmed	   in	   the	   same	   publication	   by	   the	  asymmetric	   aziridination	   of	   acetal-­‐containing	   aldimine,	   63,	   with	   ethyl	   diazoacetate,	  mediated	   by	   N-­‐fluoropyridinium	   trifluoromethanesulfonate,	   after	   which	   the	  preservation	  of	  the	  acetal	  moiety	  was	  observed	  (See	  Scheme	  19).	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59, X = N
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Scheme	  20.	  	  Cahard	  et	  al.’s	  synthesis	  of	  BMS-­‐Maxipost™,	  69,	  using	  and	  fluorinated	  dihydroquinidine	  derivative,	  68,	  as	  an	  electrophilic	  fluorinating	  agent.	  An	   aim	   of	   this	   study	   is	   to	   test	   the	   hypothesis	   that	   the	   aza-­‐Darzens	   reaction	   can	   be	  mediated	  by	  the	  same	  class	  of	  [N-­‐F]+	  alkaloids	  as	  used	  in	  aforementioned	  electrophilic	  fluorination	  reactions.	  Reactions	  mediated	  by	  fluorinated	  alkaloid	  salts	  will	  be	  similar	  to	  reactions	   carried	   out	   using	   60,	   with	   the	   key	   exception	   of	   the	   presence	   of	   the	  stereocentres	   of	   the	   alkaloid.	   A	   chiral	   intermediate	  may	   be	   formed	   through	   “Halogen	  Bonding”	  between	  the	  catalyst	  and	  substrate.32	  The	  formation	  of	  such	  an	  intermediate	  might	   hinder	   the	   approach	   of	   ethyl	   diazoacetate	   in	   an	   aza-­‐Darens	   aziridination	   and	  produce	  an	  enantiomeric	  excess	  of	  aziridine	  product	  (See	  Scheme	  21).	  Variation	  of	   the	  
O-­‐protecting	  group	  may	  be	  used	  to	  alter	  both	  steric	  and	  electronic	  properties	  of	  catalyst,	  affecting	  any	  observed	  yields	  and/or	  enantiomeric	  excesses	  (See	  Fig	  5.).	  
	  
Scheme	  21.	  The	  proposed	  method	  for	  the	  asymmetric	  organocatalysed	  aza-­‐Darzens	  aziridination,	  using	  O-­‐protected,	  N-­‐fluorinated	  dihydroquinidine	  derivatives	  
2.2 DABCO
1.2 68
































































Fig	  5.	  Some	  proposed	  Dihydroquinidine-­‐derived	  alkaloids	  for	  use	  in	  this	  study.	  
1.3.2 -­‐	   Imidazolium-­‐Based	   Ionic	   Liquids	   as	   Organocatalysts	   for	   the	  


















































Scheme	  22.	  Xia	  et	  al.’s	  use	  of	  80	  to	  solvate	  and	  catalyse	  the	  aza-­‐Darzens	  aziridination	  between	  aldimines	  and	  diazoacetate.	  Although	  the	  ionic	  liquid	  mediated	  reaction	  had	  previously	  established,	  Xia	  et	  al.	  offered	  no	  discussion	  regarding	  the	  mechanism	  of	  the	  reaction	  or	  as	  to	  the	  possibility	  of	  tuning	  this	  strategy	  to	  control	  the	  absolute	  stereochemistry	  of	  the	  product	  and	  so	  we	  became	  interested	   in	   answering	   some	   of	   these	   questions.	   It	   was	   therefore	   proposed	   two	  separate	   strategies	   to	  develop	  an	  asymmetric	  method,	   the	   first	   strategy	  was	   to	   install	  chirality	  into	  the	  counter-­‐anion	  of	  the	  ionic	  liquid,	  using	  a	  method	  previously	  reported	  by	   Tran	   et	   al.,	   in	   which	   imidazolium	   halide	   salts	   underwent	   an	   ion	   metathesis	   with	  chiral	  sodium	  salts	  possessing	  an	  chiral	  borate	  anion.35	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Scheme	  23.	  Above:	  The	  asymmetric	  aza-­‐Diels-­‐Alder	  reaction	  carried	  out	  by	  Vo-­‐Thanh	  
et	  al.	  mediated	  by	  asymmetric	  ionic	  liquids,	  85	  or	  86.	  Below:	  The	  proposed	  analogous	  asymmetric	  aza-­‐Darzens	  aziridination	  mediated	  by,	  85	  or	  86.	  
1.4 	  -­‐	  Methodology	  
1.4.1 -­‐	  Synthesis	  of	  O-­‐Protected	  Alkaloid	  Derivatives	  






























85, R = Ac
86, R = H
C.I.L. 85 or 86
85 = 59% e.e.
86 = 68% e.e.
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1.4.2 -­‐	  N-­‐Fluorination	  of	  O-­‐Protected	  Alkaloids	  
	  Catalytically	   active	   fluorinated	   quinidine	   alkaloids	   were	   obtained	   according	   to	   a	  procedure	   reported	   by	   Cahard	   et	   al.	   Alkaloids	   were	   stirred	   in	   the	   presence	   of	  Selectfluor™,	   leading	   to	   the	   transfer	  of	   the	   fluoronium	   ion	   to	   the	  nitrogen	  of	   the	  basic	  quinuclidine	  moiety	  along	  with	  a	  tetrafluoroborate	  counter-­‐anion.38	  Addition	  of	  sulfuric	  acid	   solution	   is	   used	   to	   precipitate	   the	   1-­‐chloromethyl-­‐4-­‐hydro-­‐1,4-­‐diazoniabicyclo[2.2.2]octane	   hydrogen	   sulphate	   tetrafluoroborate	   by-­‐product,	   making	  the	   subsequential	   re-­‐crystallisation	   of	   the	   N-­‐fluorinated	   alkaloids	   possible.	   The	  fluorinated	   alkaloid	   salts	   can	   then	   be	   used	   as	   chiral	   fluoronium	   catalysts	   for	   the	  asymmetric	  aza-­‐Darzens	  aziridination.	  
1.4.3 -­‐	   Preparation	   of	   a	   Symmetrical	   1-­‐butyl-­‐3-­‐methylimidazolium	  
Ionic	  Liquids	  
























1.4.4 -­‐	   Preparation	   of	   Chiral	   1-­‐Butyl-­‐3-­‐methylimidazolium	   Ionic	  
Liquids:	  Formation	  of	  the	  Chiral	  Borate	  Anions	  
	   	  An	   asymmetric	   strategy	   employed	  was	   the	   use	   of	   asymmetric	   ionic	   liquids	   bearing	   a	  chiral	   anion.	   Based	   on	   the	   assumption	   that	   the	   imidazolium	   acts	   as	   a	   hydrogen	   bond	  donor	   to	   activate	   imine	   substrates,	   a	   chiral	   anion	   may	   provide	   a	   suitably	   chiral	  environment	   in	   order	   to	   generate	   an	   enantiomeric	   excess	   from	   the	   aza-­‐Darzens	  aziridination.	  We	  chose	  chiral	  borate	  anions	  for	  this	  aim,	  which	  is	  easily	  of	  synthesised	  from	  very	  accessible	  starting	  materials.	  	  Formation	  of	  the	  chiral	  borate	  was	  carried	  out	  in	  accordance	  with	  a	  procedure	  reported	  by	  Leitner	  et	  al.	  by	  heating	  boric	  acid	  with	  two	  equivalents	  of	  either	  (S)-­‐malic	  or	  (S)-­‐mandelic	  acid	  in	  the	  presence	  of	  one	  equivalent	  of	  aqueous	   sodium	   hydroxide,	   allowing	   for	   evaporation	   of	   all	   water	   to	   give	   the	   chiral	  sodium	  borate	  salts.40	  	  
1.4.5 -­‐	   Preparation	   of	   Chiral	   1-­‐Butyl-­‐3-­‐methylimidazolium	   Ionic	  
Liquids:	  Generation	  of	  Chiral	  1-­‐Butyl-­‐3-­‐methylimidazolium	  Salts	  






























1.4.6 -­‐	  Isosorbide-­‐Derived	  Imidazolium	  Chiral	  Ionic	  Liquid:	  Selective	  -­‐
O-­‐protection	  of	  the	  Isosorbide	  scaffold	  
	   	  The	   alternative	   asymmetric	   ionic	   liquid	   strategy	   involved	   the	   synthesis	   of	   an	  imidazolium	   ionic	   liquid	   bearing	   chirality	   on	   the	   cation.	  We	   chose	   to	   target	   a	   species	  reported	   recently	   by	  Vo-­‐Thanh	  et	   al.,	   a	   chiral	   isomannide	  molecule	   singly	   substituted	  with	   an	   imidazolium	   moiety	   and	   trifluoromethansulfonate	   anion.41	   The	   synthesis	  actually	   begins	   with	   isosorbide	   (a	   diastereomer	   of	   isomannide)	   and	   involves	   the	  selective	  mono-­‐acetylation	   of	   the	   endo-­‐hydroxy	   group	   using	   a	   procedure	   reported	   by	  Stoss	  et	  al.,	   stirring	   isosorbide	   in	   the	  presence	  of	  a	   little	  over	  one	  equivalent	  of	  acetic	  anhydride	  and	  a	  catalytic	  amount	  of	  lead(II)oxide.42	  Having	  protected	  the	  endo-­‐hydroxy	  group,	   the	   next	   step	   of	   this	   synthesis	   replaces	   the	   exo-­‐hydroxy	   group	   with	   the	  trifluoromethanesulfonate	  leaving	  group.	  This	  is	  achieved	  first	  by	  deprotonation	  of	  the	  isosorbide	   with	   pyridine	   and	   followed	   by	   the	   low-­‐temperature	   slow	   addition	   of	   a	  stoichiometric	  amount	  of	  trifluoromethanesulfonic	  anhydride.	  	  
1.4.7 	  -­‐	  Isosorbide-­‐Derived	  Imidazolium	  Chiral	  Ionic	  Liquid:	  
Nucleophilic	  Substation	  of	  the	  Trifluoromethansulfonate	  
Leaving	  Group	  






















trifluoromethansulfonate	   in	   solvent-­‐free	   conditions	   for	   2	   days.41	   An	   SN2	   type	  substitution	   occurs	   during	   this	   time,	   resulting	   in	   the	   displacement	   of	   the	  trifluoromethansulfonate	   with	   the	   imidazolium	   moiety.	   This	   step	   also	   leads	   to	   the	  inversion	  of	  stereochemistry	  of	  the	  concerned	  carbon	  centre,	  converting	  the	  isosorbide	  scaffold	  into	  that	  of	  an	  isomannide	  one	  and	  giving	  quite	  a	  restricted	  chiral	  environment	  around	   the	   imidazolium	  moiety.	   It	   is	   hypothesised	   that	   this	   gives	   a	   high	   likelihood	  of	  producing	   enantiomeric	   excess	   when	   employed	   as	   a	   catalyst	   for	   the	   aza-­‐Darzens	  aziridination.	  It	  is	  noteworthy	  that	  the	  reaction	  time	  of	  the	  SN2	  step	  is	  long	  and	  therefore	  makes	   the	   synthesis	   less	   attractive.	   Many	   new	   protocols	   for	   the	   formation	   of	   ionic	  liquids	   employing	   the	   use	   of	   microwave	   radiation	   have	   been	   reported,	   often	   greatly	  reducing	   reaction	   times.43	   It	   was	   also	   therefore	   proposed	   to	   investigate	   the	   use	   of	  microwaves	  in	  this	  step	  with	  the	  aim	  of	  increasing	  the	  reaction	  rate.	  	  	   	  
25	  	  
2 	  -­‐	  Results	  and	  Discussion	  
2.1 	  -­‐	  Synthesis	  of	  O-­‐Protected	  Alkaloid	  Derivatives	  All	  O-­‐protected	  alkaloids	  were	  formed	  by	  the	  same	  general	  procedure	  of	  deprotonation	  at	   the	   alcohol	   group	   of	   the	   alkaloid	   molecule	   using	   a	   base	   to	   deprotonate	   and	  subsequent	  substitution	  with	  an	  appropriate	  acyl	  chloride	  or	  chloride.	  All	  acyl	  chloride	  examples	   required	   only	   triethylamine	   as	   the	   base	   for	   the	   deprotonation	   step,	   the	  resultant	   deprotonated	   alkaloid	   reacts	   with	   acyl	   chlorides	   vigorously	   and	  exothermically.	   It	  was	  necessary	   for	  acyl	  chlorides	   to	  be	  added	  slowly	  and	  at	  reduced	  temperature.	  	  The	  resultant	  O-­‐protected	  alkaloids	  were	  washed	  with	  aqueous	  saturated	  sodium	   hydrogen	   carbonate	   solution	   and	   the	   free	   alkaloid	   bases	   were	   found	   to	   re-­‐crystalise	  from	  methanol.	  The	   reaction	   of	   1,4-­‐dichlorophthalazine	   with	   two	   equivalents	   of	   dihydroquinidine	  required	  relatively	  harsh	  conditions.	  In	  this	  case,	  a	  combination	  of	  potassium	  hydroxide	  and	   potassium	   carbonate	   bases	   were	   implemented	   for	   the	   deprotonation	   step.	  Inorganic	   bases	   are	   considerably	   stronger	   than	   pyridine	   and	   bring	   about	   a	   more	  absolute	  deprotonation	  of	   the	   alkaloid.	   The	  mixture	   of	   the	  deprotonated	   alkaloid	   and	  1,4-­‐dichlorophthalazine	   required	   refluxing	   with	   the	   aziotropic	   removal	   of	   water	  overnight	  for	  complete	  conversion.	  The	  ammonium	  hydrogen	  sulfate	  salt	  of	  the	  alkaloid	  was	   first	   precipitated	   using	   sulfuric	   acid	   and	   the	   free	   base	  was	   then	   re-­‐generated	   by	  washing	   with	   aqueous	   with	   aqueous	   saturated	   sodium	   hydrogen	   carbonate	   solution	  and	  the	  free	  alkaloid	  base	  was	  then	  re-­‐crystallised	  from	  warm	  methanol.	  
	  
Fig.7	  An	  Ortep	  representation	  of	  the	  crystals	  structure	  of	  72.	  The	  hydrogen	  atoms	  are	  omitted	  for	  sake	  of	  clarity.	  Thermal	  ellipsoids	  are	  drawn	  at	  50%	  probability	  level.	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Figure	  8.	  An	  Ortep	  representation	  of	  two	  independent	  molecules	  of	  75.	  All	  Hydrogen	  atoms	  are	  omitted	  for	  clarity.	  Thermal	  ellipsoids	  are	  drawn	  at	  50%	  probability	  level.	  All	   alkaloids	   generated	   for	   the	   purposes	   of	   this	   study	   were	   found	   to	   be	   highly	  hygroscopic,	   however	   degrees	   of	   hygroscopicity	   varied	   depending	   on	   O-­‐functionalisation.	   Some	   alkaloid	   derivatives	   synthesised	   were	   found	   to	   be	   so	  hygroscopic	  that	  removal	  of	  water	  and	  re-­‐crystalisation	  without	  a	  very	  dry	  atmosphere	  was	  not	  possible	  and	  thus	  these	  were	  impractical	  to	  purify	  (See	  Fig	  9.).	  
	  
Fig	  9.	  Alkaloid	  species	  that	  were	  synthesised	  but	  not	  isolated	  or	  used	  further	  for	  this	  study.	  
2.2 	  -­‐	  N-­‐Fluorination	  of	  O-­‐Protected	  Alkaloids	  
























the	   appropriate	   alkaloid	   derivative	   in	   acetonitrile	   for	   use	   in	   asymmetric	   electrophilic	  fluorination.45	  Using	   this	   technique	   removed	   the	  need	   to	  purify	   chiral	   [N-­‐F]+	   reagents	  and	   avoided	   the	   storage	   of	   the	   highly	   hygroscopic	   salts.	   It	   was	   important	   before	  proceeding	  in	  this	  manner	  to	  confirm	  the	  presence	  of	  the	  correct	  F+	  species	  was	  present	  in	   the	   reaction	   mixture	   and	   determine	   the	   time	   it	   took	   before	   Selectfluor™	   was	   no	  longer	  observed	   in	   the	   fluorinated	   form.	   In	  order	   to	  obtain	   this	   information,	  a	  0.05	  M	  reaction	   solution	  of	  97	   and	   alkaloid	  78	   in	   acetonitrile-­‐d3	  was	   added	   to	   an	  NMR	   tube	  and	  observed	  using	  19F-­‐NMR	  (Scheme	  24,	  Fig	  11)	  this	  was	  referenced	  against	  a	  solution	  of	  97	  in	  acetonitrile-­‐d3	  (Scheme	  24,	  Fig	  10).	  	  	  	  
	  
Fig	  10.	  The	  19F-­‐NMR	  of	  Selectfluor™,	  97	  in	  acetonitrile-­‐d3.	  
	  	  



































Fig	  11.	  The	  19F-­‐NMR	  of	  97	  in	  combination	  with	  78	  in	  acetonitrile-­‐d3.	  In	   the	   time	   that	   elapsed	  between	   loading	   the	  NMR	   tube	   and	  performing	   the	   first	   19F-­‐NMR	   scan,	   the	   reaction	   could	   already	   be	   observed	   to	   be	   complete,	   as	   the	   fluoronium	  signal	  had	  shifted	  up-­‐field	  from	  48.00	  ppm	  in	  the	  reference	  sample	  to	  37.42	  ppm.	  This	  difference	  of	   -­‐10.58	  ppm	   indicates	   that	   the	   fluorine	   atom	   situated	   at	   the	  quinuclidine	  moiety	   of	   98	   is	   significantly	   more	   shielded	   by	   electron	   density	   than	   the	   equivalent	  fluorine	  atom	   in	  97.	  This	  observation	   is	   in	  agreement	  with	   logic,	   as	   the	   fluorine	  atom	  has	  transferred	  from	  a	  di-­‐cationic	  environment	  to	  a	  mono-­‐cationic	  one,	  which	  is	   likely	  to	  be	  more	   susceptible	   to	  polarisation	  by	   the	  electronegative	   fluorine	  atom.	  This	  may	  also	   indicate	  that	  98	  has	  a	  reduced	  capacity	  to	  act	  as	  a	  Lewis	  acid	  with	  respect	   to	  97,	  this	  would	   not	   have	   any	   significant	   adverse	   consequences	   in	   the	   case	   of	   electrophilic	  fluorination	   (as	   reaction	  with	   a	   carbanion	   is	   thermodynamically	   very	   favourable)	   but	  may	   be	   responsible	   for	   observed	   adverse	   effects	   on	   the	   catalytic	   rate,	   which	   will	   be	  discussed	  in	  the	  next	  section.	  	  
2.3 	  -­‐	  Aziridination	  with	  F+	  Catalysts	  Seven	  of	  the	  most	  readily	  purified	  and	  thus,	  most	  accessible	  alkaloid	  derivatives	  69,	  72-­‐




Figure	  12.	  Chiral	  [N-­‐F]+	  catalysts	  generated	  for	  preliminary	  screening.	  Once	   chiral	   [N-­‐F]+	   species	  were	   formed	   in	   situ	   by	   following	   the	   procedure	   set	   out	   by	  Shibata	   et	   al.,	   aziridinations	  were	   carried	   out	   by	   adding	   an	   aldimine	   substrate	   to	   the	  solution	  and	  1	  equivalent	  of	  ethyl	  diazoacetate.	  Reactions	  were	  monitored	  by	  extraction	  of	   a	   small	   sample	   of	   crude	   reaction	  mixture	   and	   subsequent	   1H-­‐NMR	   analysis	   of	   the	  sample.	  
	  





















































































[N-­‐F]+	  catalysta	   yield	  (%)	   %	  e.e.	  
100	   23	   Racemicb	  
101	   33	   Racemicc	  
102	   8	   Racemicc	  
103	   0d	   N/A	  
104	   18	   Racemicc	  
105	   13	   Racemicc	  
106	   20	   Racemicc	  	  
Table	  1.	  Yields	  and	  e.e.s	  for	  the	  formation	  of	  108	  using	  fluorinated	  alkaloid	  catalysts	  and	  EDA.	  a)	  Catalysts	  were	  generated	  in	  situ	  from	  10	  mol%	  of	  either	  69,72-­‐76	  or	  78	  in	  combination	  with	  10	  mol%	  of	  Selectfluor,	  98	  in	  acetonitrile	  at	  ambient	  temperature.	  b.)	  Racemate	  identified	  using	  a	  Chiralpak	  HPLC	  column	  and	  optical	  polarimetry.	  c)	  Racemate	  identified	  using	  optical	  polarimetry	  only.	  d)	  Minimal	  aziridine	  product	  observed	  by	  1H-­‐NMR	  observation	  of	  crude	  mixture,	  but	  not	  isolated.	  The	  first	  screening	  of	   the	  chiral	   [N-­‐F]+	  catalysts	   involved	  the	  transformation	  of	   	   (E)-­‐2-­‐Butoxy-­‐N-­‐(4-­‐nitrobenzylidene)phenylamine,	   107	   into	   aziridine	   108	   (See	   Scheme	   25).	  
107	  was	  selected	  due	  to	  a	  bulky,	  electron-­‐donating	  tert-­‐butoxy	  group	  situated	  ortho	  on	  the	   aniline	   ring,	   which	   could	   possibly	   enhance	   enantioselectivity	   through	   steric	  interactions	   and	   also	   donates	   electron	   density	   to	   activate	   the	   aldimine	   towards	   the	  forming	   an	   adduct	   with	   catalysts.	   This	   particular	   aldimine	   also	   bears	   an	   electron	  withdrawing	   para-­‐nitrobenzene	   moiety,	   which	   activates	   the	   α-­‐carbon	   of	   the	   imine	  towards	   nucleophilic	   attack	   by	   ethyl	   diazoacetate.	   	   Rates	   of	   reaction	   for	   this	  substrate/catalyst	  combination	  were	  slow,	  reactions	  were	  permitted	  to	  proceed	  for	  48	  h	  and	  then	  purified	  via	  column	  chromatography.	  Yields	  are	  notably	  poor	  and	  range	  from	  8%	  -­‐	  33%.	  Catalyst	  103	  failed	  to	  produce	  any	  recoverable	  yield	  at	  all,	  however	  minimal	  aziridine	   product	   was	   observed	   in	   the	   crude	   1H-­‐NMR	   of	   the	   reaction	   mixture.	   All	  reaction	   products	   gave	   [α]20D	   =	   0	   (c	   =	   1.0,	   CHCl3),	   indicating	   that	   no	   excess	   of	   chiral	  species	  was	  present	  (See	  Table	  1.).	  When	  observing	  the	  separation	  of	  the	  two	  aziridine	  enantiomers	  when	  run	  through	  a	  chiralpak	  HPLC	  column	  and	  eluted	  with	  2%	  MeOH	  in	  iPrOH,	  the	  mixture	  could	  be	  seen	  to	  be	  racemic.	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Scheme	  26.	  The	  aziridination	  of	  aldimine	  109	  and	  EDA,	  using	  fluorinated	  alkaloid	  catalysts.	  
	  
[N-­‐F]+	  catalysta	   yield	  (%)	   %	  e.e.	  
100	   5	   Racemicb	  
101	   8	   Racemicc	  
102	   0d	   N/A	  
103	   0d	   N/A	  
104	   5	   Racemicc	  
105	   8	   Racemicc	  
106	   13	   Racemicc	  	  
Table	  2.	  Yields	  and	  e.e.s	  for	  the	  aziridination	  of	  109	  using	  fluorinated	  alkaloid	  catalysts	  and	  EDA.	  a)	  Catalysts	  were	  generated	  in	  situ	  from	  10	  mol%	  of	  either	  69,72-­‐76	  or	  78	  in	  combination	  with	  10	  mol%	  of	  Selectfluor,	  97	  in	  acetonitrile	  at	  ambient	  temperature.	  b.)	  Racemate	  identified	  using	  a	  Chiralpak	  HPLC	  column	  and	  optical	  polarimetry.	  c)	  Racemate	  identified	  using	  optical	  polarimetry	  only.	  d)	  Minimal	  aziridine	  product	  observed	  by	  1H-­‐NMR	  observation	  of	  crude	  mixture,	  but	  not	  isolated.	  
	  





























[N-­‐F]+	  catalysta	   yield	  (%)	   %	  e.e.	  
100	   47	   Racemicb	  
101	   52	   Racemicc	  
102	   38	   Racemicc	  
103	   15	   Racemicc	  
104	   47	   Racemicc	  
105	   49	   Racemicc	  
106	   54	   Racemicc	  	  
Table	  3.	  Yields	  and	  e.e.s	  for	  the	  aziridination	  of	  109	  using	  fluorinated	  alkaloid	  catalysts	  and	  EDA.	  a)	  Catalysts	  were	  generated	  in	  situ	  from	  10	  mol%	  of	  either	  69,72-­‐76	  or	  78	  in	  combination	  with	  10	  mol%	  of	  Selectfluor,	  97	  in	  acetonitrile	  at	  ambient	  temperature.	  b.)	  Racemate	  identified	  using	  a	  Chiralpak	  HPLC	  column	  and	  optical	  polarimetry.	  c)	  Racemate	  identified	  using	  optical	  polarimetry	  only.	  Further	  attempts	  were	  made	  to	  asymmetrically	  catalyse	  the	  aza-­‐Darzens	  reaction	  with	  the	   chiral	   [N-­‐F]+	   catalysts.	   The	   aldimine	   substrate,	   (E)-­‐4-­‐methoxy-­‐N-­‐(benzylidene)phenylamine,	   109,	   (See	   Scheme	   26)	   was	   used	   as	   this	   much	   less	  functionalised	  molecule	  and	  was	  used	  primarily	  to	  minimise	  and	  observe	  any	  affects	  on	  yield	  or	  enantioselectivity	  that	  substituents	  may	  have	  and	  thus	  can	  be	  considered	  as	  a	  reference	  aldimine	  substrate.	  The	  replacement	  of	  an	  electron-­‐withdrawing	  group	  with	  benzylidene	  results	  in	  significantly	  reduced	  yields.	  As	  with	  the	  aziridination	  of	  108,	  all	  samples	   of	   aziridine	   product,	  110,	   give	   [α]20D	   =	   0	   (c	   =	   1.0,	   CHCl3),	   indicating	   that	   no	  excess	  of	  chiral	  species	  is	  present	  (See	  Table	  2).	  When	  observing	  the	  separation	  of	  the	  two	  aziridine	  enantiomers	  when	  run	  through	  a	  chiralpak	  HPLC	  column	  and	  eluted	  with	  5%	  MeOH	  in	  iPrOH,	  the	  mixture	  can	  be	  seen	  to	  be	  racemic.	  	  The	   (E)-­‐4-­‐methoxy-­‐N-­‐(2-­‐pyridinylidene)phenylamine,	   111,	   was	   also	   observed	   under	  identical	   aziridination	   conditions	   as	   the	   previous	   two	   runs	   (See	   Scheme	   27).	   The	  presence	   of	   the	   electron	  withdrawing	   2-­‐pyridinylidene	   group	   has	   a	   positive	   effect	   on	  the	   yield	   of	   the	   reaction,	   producing	   yields	  within	   the	   range	   of	   15-­‐52	  %.	  However,	   all	  samples	  of	  aziridine	  product,	  112,	  [α]20D	  =	  0	  (c	  =	  1.0,	  CHCl3),	  indicating	  that	  no	  excess	  of	  chiral	  species	  is	  present	  (See	  Table	  3).	  Observation	  of	  the	  separation	  of	  the	  two	  aziridine	  enantiomers	  when	  run	  through	  a	  chiralpak	  HPLC	  column	  and	  eluted	  with	  10%	  MeOH	  in	  iPrOH,	  the	  mixture	  could	  be	  seen	  to	  be	  racemic.	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Aziridination	  of	  substrates	  107,	  109	  and	  111	  were	  also	  mediated	  by	  non-­‐chiral	  60	  and	  later	   also,	   for	   the	   first	   time	   using	   97,	   producing	   very	   similar	   catalytic	   activity	   (See	  
Scheme	  28).	  These	  reactions	  were	  carried	  out	  to	  provide	  racemic	  samples	  of	  aziridines	  
108,	  110	  and	  112.	  
	  
Scheme	  28.	  Aziridination	  reactions	  mediated	  by	  achiral	  60	  or	  97.	  
































































Upon	   further	   consideration	   of	   the	   mechanism	   of	   these	   reactions	   it	   is	   possible	   to	  hypothesise	   a	   probable	   cause	   for	   the	   formation	   of	   racemic	   aziridine	   products.	   As	  aforementioned,	   this	   study	  assumes	   the	   formation	  of	   a	   complex	  between	   catalyst	   and	  substrate,	  forming	  a	  chiral	  adduct	  and	  biasing	  ethyl	  diazoacetate	  to	  approach	  one	  face	  of	  the	  activated	  imine	  more	  frequently	  than	  from	  the	  other.	  However,	  it	  is	  entirely	  possible	  that	   the	   activation	   of	   the	   aldimine	   substrate	   goes	   via	   a	   slightly	   different	   pathway,	  whereby	   the	   fluorine	   ion	   dissociates	   completely	   from	   the	   alkaloid,	   giving	   a	   cationic	  fluoro-­‐iminium	   species	  with	   an	   achiral	   tetrafluoroborate	   anion	   and	   a	   neutral	   alkaloid	  base	   (See	   Scheme	   29).	   Importantly,	   this	   proposed	   mechanism	   give	   a	   symmetrical	  activated	  substrate	  and	  therefore	  accounts	  for	  the	  formation	  of	  racemic	  product.	  
	  































Scheme	  30.	  The	  attempted	  N-­‐fluorination	  of	  phosphoramide,	  113.	  Attempts	  were	   also	  made	   to	   generate	   an	   [N-­‐F]+	   salt	   containing	   a	   chiral	   anion.	   Chiral	  sodium	   borate	   salts	  90	   and	  91	   had	   already	   been	   synthesised	   for	   use	   in	   synthesising	  chiral	  ionic	  liquids	  and	  an	  ion	  metathesis	  between	  Selectfluor,	  60	  and	  89	  in	  acetone	  was	  attempted	   (See	   Scheme	   31).	   However	   the	   expectation	  was	   that,	   if	   the	  metathesis	  was	  favourable,	   it	   would	   result	   in	   the	   precipitation	   of	   solid	   sodium	  trifluoromethanesulfonate,	  116	   from	  the	  solution	  and	   this	  was	  not	  observed	  and	   thus	  unlikely	  that	  a	  metathesis	  had	  occurred	  between	  the	  two.	  Separation	  of	  the	  mixture	  was	  achieved	  by	  concentrating	  the	  mixture	  in	  vacuo	  and	  the	  addition	  of	  dichloromethane	  to	  produce	  a	  precipitate,	  which	  was	  identified	  as	  being	  the	  starting	  material,	  89.	  
	  
Scheme	  31.	  The	  attempted	  ion	  metathesis	  between	  60	  and	  89	  In	   order	   to	   successfully	   synthesise	   an	   [N-­‐F]+	   salt	   bearing	   a	   chiral	   anion,	   one	   might	  consider	   the	   industrial	   synthesis	   of	  N-­‐fluoropyridinium	   salts,	   which	   is	   carried	   out	   in	  accordance	   with	   a	   procedure	   reported	   by	   Umemoto	   et	   al.	   in	   1991.46	   The	   method	  
a.) 1.0 eq KH













































involves	  the	  reaction	  of	  pyridine	  with	  elemental	  fluorine	  at	  low	  temperatures	  to	  yield	  N-­‐fluoropyridinium	  fluoride,	  which	  is	  not	  stable	  above	  -­‐40	  °C.	  The	  fluoride	  salt	  then	  reacts	  with	  a	  sodium	  salt	  of	   the	  desired	  anion,	  which	  is	  either	  added	  or	  present	   in	  the	   initial	  mixture	  in	  the	  case	  of	  a	  one-­‐pot	  reaction.	  Umemoto	  et	  al.	  reportedly	  generated	  in	  excess	  of	   60	   different	   N-­‐fluoropyridinium	   salts	   incorporating	   11	   various	   anions	   including	  sulphonates,	   phosphates	   and	   perchoroate,	   highlighting	   the	   versatility	   of	   this	   reaction	  with	   regards	   to	   the	   type	   of	   anion	   used.	   It	   is	   therefore	   proposed	   that	   an	   analogous	  reaction	   of	   pyridine,	  117	   with	   F2	   in	   the	   presence	   of	  89	   would	   produce	   chiral	   anion-­‐bearing	  [N-­‐F]+	  salt,	  115.	  There	   is	  a	   tremendous	  scope	   for	   the	  number	  of	  chiral	  anions	  that	   could	   be	   utilised	   for	   this	   aim,	   for	   example	   the	   chiral	   Δ-­‐tris(tetrachlorobenzene	  diolato)phosphate(V)	  (Δ-­‐TRISPHAT),	  the	  sodium	  salt	  of	  which	  is	  easily	  obtainable	  from	  commercially	  available	  [cinchonidinium][Δ-­‐TRISPHAT]	  (See	  Scheme	  32).47,48,49	  
	  
Scheme	  32.	  (above)	  The	  synthesis	  of	  60	  detailed	  by	  Umemoto	  et	  al.	  (middle	  and	  below)	  The	  hypothetical	  synthesis	  of	  chiral	  anion-­‐bearing	  N-­‐fluoropyridinium	  salts,	  115	  and	  




















































































The	   arrival	   at	   this	   particular	   conclusion	   not	   only	   provides	   a	   viable	   solution	   to	   the	  problem	  but	  also	  places	  that	  solution	  outside	  the	  capabilities	  of	  the	  Bew	  research	  group.	  The	  use	  and	  storage	  of	  elemental	   fluorine	   is	  extremely	  hazardous	  and	  requires	  highly	  specialised	  equipment	  and	  safety	  protocols	   that	  are	  not	  realistically	  obtainable	  within	  the	  group	  due	  to	  cost	  and	  safety	  considerations.	  
2.5 	  -­‐	  Synthesis	  of	  a	  Symmetrical	  1-­‐butyl-­‐3-­‐methylimidazolium	  Ionic	  
Liquid	  
	  
Scheme	  33.	  The	  synthesis	  of	  87	  and	  88	  Symmetrical	  1-­‐butyl-­‐3-­‐methyl	  ionic	  liquids	  were	  produced	  using	  a	  procedure	  reported	  by	  Dupont	  et	  al.	  (See	  Scheme	  33),	  whereby	  a	  mixture	  of	  1-­‐methylimidazole,	  120,	  and	  1-­‐chlorobutane	   were	   refluxed	   in	   acetone	   for	   48	   hr,	   followed	   by	   the	   addition	   of	   ethyl	  acetate	   and	   recrystallisation	   at	   -­‐40	   °C,	   to	   yield	  87.39	   Potassium	   hexafluorophosphate	  could	  then	  be	  added	  to	  an	  aqueous	  solution	  of	  87	  to	  form	  80	  which	  is	  immiscible	  with	  water	  and	  can	  be	  easily	  extracted	  and	  dried	  and	  was	  pure	  enough	  to	  be	  used	  without	  further	  purification.	  
2.6 	  -­‐	  Preparation	  of	  Chiral	  1-­‐Butyl-­‐3-­‐methylimidazolium	  Ionic	  
Liquids:	  Synthesis	  of	  the	  Chiral	  Borate	  Anions	  Formation	  of	   chiral	   sodium	  borate	   salts	  were	   formed	   in	  accordance	  with	  a	  procedure	  reported	  by	  Leitner	  et	  al.,	  in	  which	  either	  maleic	  acid,	  121,	  or	  mandelic	  acid,	  122	  were	  heated	   to	   100	   °C	   in	   the	   presence	   of	   boric	   acid	   and	   aqueous	   sodium	   hydroxide	   (See	  


















Scheme	  34.	  The	  mechanism	  by	  which	  the	  chiral	  sodium	  borate	  salts	  88	  and	  89	  are	  generated	  from	  121	  and	  122	  respectively.	  
2.7 -­‐	  	  Preparation	  of	  Chiral	  1-­‐Butyl-­‐3-­‐methylimidazolium	  Ionic	  
Liquids:	  Synthesis	  of	  Chiral	  1-­‐Butyl-­‐3-­‐methylimidazolium	  Salts.	  
	  	  

















































































88, R = CH2CO2H
89, R = Ph
90, R = CH2CO2H
91, R = Ph
39	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Fig.	  13	  Energy-­‐minimised	  3D	  representations	  of	  chiral	  ionic	  liquids	  90	  (left)	  and	  91	  (right)	  rendered	  using	  Cambridgesoft	  Chem3D	  software	  (hydrogen	  atoms	  and	  lone	  electron-­‐pairs	  have	  been	  omitted	  for	  simplicity).	  Chiral	   ionic	   liquids	   90	   and	   91	   were	   synthesised	   by	   mixing	   1-­‐butyl-­‐3-­‐methyl	  imidazolium	  chloride,	  87,	   in	  a	  solution	  of	  acetone	  with	  the	  appropriate	  sodium	  borate	  salt.	  Immediately	  solid	  sodium	  chloride	  salt	  started	  to	  precipitate,	  and	  after	  an	  hour,	  the	  solution	  was	  filtered	  and	  concentrated	  in	  vacuo	  to	  give	  the	  desired	  chiral	  ionic	  liquid	  in	  a	  quantitative	   yields,	  which	  was	  pure	   enough	   to	  use	  without	   further	  purification	   (See	  
Scheme	  35).	  
2.8 	  -­‐	  Isosorbide-­‐Derived	  Imidazolium	  Chiral	  Ionic	  Liquid:	  Selective	  O-­‐
Protection	  of	  the	  Isosorbide	  Scaffold	  
	  

























the	   relatively	   large	   lead	   centre	   coordinates	   to	   the	   exo	   alcoholic	   oxygen,	   effectively	  blocking	  it	  from	  acetylation	  (See	  Scheme	  37).	  	  
	  	  
Scheme	  37.	  An	  illustration	  of	  how	  a	  lead	  cation	  blocks	  the	  exo	  oxygen	  of	  123	  from	  acetylation,	  leading	  to	  the	  selective	  formation	  of	  93.	  The	   large	   quantity	   of	   acetic	   acid	   by-­‐product	   produced	   by	   this	   step	   was	   removed	   in	  
vacuo,	  which	  was	  a	  time-­‐consuming	  process.	  Alternatively,	  washing	  the	  crude	  product	  with	  aqueous	   sodium	  hydrogen	  carbonate	   to	   remove	   the	  organic	  acid	  was	  attempted,	  but	   92	  was	   found	   to	   be	   highly	   soluble	   in	   aqueous	   media	   and	   re-­‐extraction	   using	   a	  variety	  of	  organic	  solvents	  to	  be	  highly	  inefficient.	  Removing	  acetic	  acid	  using	  a	  reduced	  pressure	  distillation	  at	  10	  mbar	  was	  attempted,	  however	  at	   this	  pressure	  heating	  was	  required	  to	  evaporate	  acetic	  acid.	  After	  distillation	  a	  crystalline	  solid	  was	  recovered	  and	  it	   was	   found	   that	   heating	   had	   been	   sufficient	   to	   initiate	   an	   intramolecular	   trans-­‐esterification,	   resulting	   in	   the	   thermodynamically	   favoured	   isomer,	   124	   (See	   Scheme	  
38).	  
	  
Scheme	  38.	  The	  unintended	  intramolecular	  trans-­‐esterification	  of	  92	  to	  124	  as	  a	  result	  of	  heating.	  





























Fig	  14.	  The	  minor	  bis-­‐acetylated	  byproduct	  produced	  during	  the	  synthesis	  of	  92.	  Triflation	   of	   the	   remaining	   alcohol	   group	   of	   92	   was	   then	   achieved	   according	   to	   a	  procedure	  set	  out	  by	  Vo-­‐Thanh	  et	  al.,	  involving	  the	  deprotonation	  of	  92	  using	  pyridine,	  
117,	   in	   dichloromethane	   and	   the	   subsequent	   reaction	   with	   trifluoromethanesulfonic	  anhydride,	   125	   (See	   Scheme	   39).	   Washing	   the	   crude	   organic	   solution	   with	   water	  followed	  by	  an	  aqueous	  5	  M	  aqueous	  hydrochloric	   acid	   solution	  purified	   the	  product,	  
93.	   It	   is	   noteworthy	   that	   93	   tolerates	   5	   M	   hydrochloric	   acid	   and	   does	   not	   undergo	  elimination	  of	  the	  trifluoromethanesulfonate	  group,	  this	  is	  indicative	  of	  high	  stability	  for	  a	   trifluoromethanesulfonate-­‐protected	   molecule.	   Subsequently,	   93	   was	   recovered	   by	  drying	  and	  removal	  of	  solvent	  in	  vacuo	  in	  a	  good	  yield	  and	  was	  pure	  enough	  for	  further	  steps.	  
	  	  	  	  
Scheme	  39.	  The	  mechanism	  by	  which	  the	  remaining	  alcohol	  group	  of	  92	  is	  replaced	  with	  trifluoromethanesulfonate.	  
2.9 	  -­‐	  Isosorbide-­‐Derived	  Imidazolium	  Chiral	  Ionic	  Liquid:	  
Nucleophilic	  Substitution	  of	  the	  Trifluoromethanesulfonate	  

































an	   SN2	   nucleophilic	   substitution	   with	   120,	   which	   displaces	   the	  trifluoromethanesulfonate	   group	   and	   installs	   it	   as	   the	   cation	   of	   the	   ionic	   liquid	  while	  simultaneously	   inverting	   the	   stereochemistry	   of	   the	   concerned	   carbon	   centre.	   This	  results	   in	   the	  restricted,	   concave,	   chiral	  and	   imidazolium-­‐bearing	  structure	  of	  94.	  The	  organocatalytic	   properties	   of	   94	   make	   themselves	   apparent	   immediately	   in	   this	  procedure;	   it	   seems	   that	   94	   mediates	   the	   elimination	   of	   the	   relatively	   stable	  trifluoromethanesulfonate	   functionality	   of	   93,	   resulting	   in	   approximately	   one	  equivalent	  of	  the	  elimination	  product,	  127	  (See	  Scheme	  40).	  	  
	  






























































Scheme	  41.	  The	  microwave-­‐assisted	  synthesis	  of	  94.	  Separation	  of	  residual	  120	  and	  94	  has	  proven	  extremely	  difficult	  to	  date	  and	  has	  not	  yet	  been	  achieved	   in	   this	  study.	  Vo-­‐Thanh	  et	  al.	  describe	  a	  chromatography	  column	  using	  alumina	  as	  the	  stationary	  phase	  and	  dichloromethane	  and	  methanol	  (methanol	  starting	  at	   0%	  with	   gradual	   increase	   to	   15%).	   However	   attempts	   to	   duplicate	   only	   served	   to	  remove	  most	  of	  elimination	  product,	  127	  and	  was	  not	  adequate	  to	  separate	  94	  and	  120.	  
	  






























Fig	  16.	  The	  1H-­‐NMR	  of	  the	  crude	  reaction	  mixture	  containing	  94	  and	  120	  in	  acetone-­‐d6	  (anotated	  and	  colour-­‐coded)	  The	  crude	  1H-­‐NMR	  of	  this	  mixture	  shows	  strong	  evidence	  of	  the	  presence	  of	  94	  (See	  Fig.	  16)	  Three	  singlets	  at	  9.20,	  7.83	  and	  7.73	  ppm	  signify	  the	  thre	  protons	  of	  an	  imidazolium	  ring,	   which	   are	   clearly	   separate	   from	   the	   analogous	   protons	   of	   the	   residual	   120.	   A	  singlet	  at	  4.07	  ppm	  indicates	  the	  presence	  of	  the	  N-­‐methyl	  group,	  again	  clearly	  separate	  from	  the	  analogous	  N-­‐methyl	  signal	  of	  120.	  
2.10 -­‐	  Aziridination	  Mediated	  by	  Imidazolium	  Ionic	  Liquid	  Catalysts	  -­‐	  	  




























Scheme	  42.	  The	  aziridination	  of	  aldimine	  111	  mediated	  by	  80.	  Chiral	  ionic	  liquids	  90	  and	  91	  were	  also	  used	  to	  mediate	  the	  aziridination	  of	  111	  and	  .	  Due	   to	   the	   very	   high	   viscosity	   of	   these	   ionic	   liquids	   in	   comparison	   with	   80,	   it	   was	  necessary	  to	  add	  small	  amount	  of	  dichloromethane	  (a	  few	  drops	  per	  1	  mL)	  in	  order	  to	  make	  stirring	  possible.	  Solutions	  of	  111	  and	  ethyl	  diazoacetate	  were	  prepared	  in	  90	  and	  
91	   respectively	  and	  were	  stirred	   for	  16	  h	  (See	  Scheme	  43).	  Both	   ionic	   liquid	  solutions	  generated	  aziridine	  112,	  however	  both	  samples	  of	  aziridine	  product	  gave,	  [α]20D	  =	  0	  (c	  =	  1.0,	  CHCl3),	  indicating	  that	  no	  excess	  of	  chiral	  species	  is	  present.	  Separation	  of	  the	  two	  aziridine	  enantiomers	  when	  run	  through	  a	  Chiralpak	  HPLC	  column	  and	  eluted	  with	  10%	  MeOH	  in	  iPrOH,	  in	  mixture	  could	  be	  observed	  to	  be	  racemic.	  
	  	  
Scheme	  43.	  The	  aziridination	  of	  aldimine	  111	  mediated	  by	  91	  or	  92.	  
2.11 -­‐	  Aziridination	  Mediated	  by	  Imidazolium	  Ionic	  Liquid	  Catalysts	  -­‐	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the	   failure	   of	   90	   or	   91	   to	   produce	   any	   enantiomeric	   excess	   at	   all	   prompted	   a	   re-­‐evaluation	  of	  the	  mechanism	  by	  which	  these	  catalysts	  mediate	  the	  aza-­‐Darzens	  reaction.	  
	  
Scheme	  44.	  The	  hypothesised	  mechanism	  for	  the	  aziridination	  of	  111	  with	  ethyl	  diazoacetate	  mediated	  by	  90	  or	  91.	  In	  order	  to	  obtain	  insight	  into	  the	  mechanism	  of	  the	  imidazolium	  ionic	  liquid-­‐catalysed	  aza-­‐Darzens	   reaction,	   it	   was	   proposed	   to	   carry	   out	   a	   test-­‐reaction	   using	   1,2-­‐dimethylimidazolium	  chloride,	  128	  (See	  Scheme	  45).	  As	  128	  is	  missing	  the	  acidic	  proton	  found	   on	   80	   and	   given	   our	   original	   hypothesis,	   should	   not	   mediate	   the	   aza-­‐Darzens	  aziridination.	  However,	  128	  successfully	  catalysed	  the	  reaction	  between	  111	  and	  ethyl	  diazoacetate,	  meaning	  that	  the	  mechanism	  of	  activation	  of	  aldimines	  by	  ionic	  liquids	  is	  not	  a	  Brønsted	  acidic	  one.	  
	  















































activated	  aldimine	  substrate	  at	  the	  moment	  of	  nucleophilic	  attack.	  This	  therefore	  leads	  to	  the	  re-­‐emphasis	  that	  the	  chiral	  ionic	  liquid	  94	   is	  in	  fact	  a	  highly	  likely	  candidate	  for	  the	   asymmetric	   catalysis	   of	   the	   aza-­‐Darzens	   aziridination	   between	   aldimines	   and	  diazoacetate,	   future	   studies	   should	   therefore	   concern	   the	   purification	   of	   this	   liquid	  catalyst	  and	  its	  application	  to	  that	  end.	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3 Experimental	  
General	  All	   reactions	  were	  carried	  out	  under	  nitrogen	  /	  argon	   in	   flame	  dried	  apparatus	  which	  were	   allowed	   to	   cool	   under	   an	   inert	   nitrogen	   atmosphere.	   Reactions	   at	   0	   °C	   were	  carried	  out	   in	  a	  water	  /	   ice	  bath.	  Reactions	  carried	  out	  at	  -­‐78	  °C	  were	  carried	  out	   in	  a	  dry	   acetone	   /	   dry	   ice	   bath.	   Solvents	   removed	   in	   vacuo	   were	   removed	   using	   either	   a	  rotary	  evaporator	  or	  a	  Genevac.	  Column	  chromatography	  was	  carried	  out	  on	  silica	  gel	  (Fluka	   silica	   gel	   60	  70	   –	   230	  mesh)	   at	   ambient	   temperature unless	   otherwise	   stated.	  TLC	  was	  carried	  out	  on	  Merck	  plates	  (aluminium	  coated	  0.2	  mm	  silica	  gel	  60	  F254)	  and	  visualised	   under	   UV	   light	   (254	   nm)	   or	   after	   exposure	   to	   an	   aqueous	   potassium	  permanganate	   solution,	   containing	  3	   g	   of	  KMnO4,	   10	   g	  K2CO3,	   2.5	  mL	  of	   aqueous	  2	  M	  NaOH	  and	  150	  mL	  of	  de-­‐ionised	  water. 
Characterisation	  Infrared	  spectra	  were	  recorded	  using	  a	  Perkin	  Elmer	  1720	  FTIR	  spectrometer.	  	  1H	  NMR,	  13C	  NMR	  and	  19F	  NMR	  spectra	  were	  recorded	  on	  Bruker	  270	  or	  300	  MHz,	  Oxford	  300	  or	  400	  MHz	  machines	   and	   samples	   are	   prepared	   as	   solutions	   of	   CDCl3	   unless	   otherwise	  stated.	  Chemical	  shifts	  (δ)	  are	  reported	  in	  parts	  per	  million	  relative	  to	  TMS	  as	  internal	  standard.	  J	  values	  are	  given	  in	  hertz.	  Mass	  spectrometry	  was	  attained	  using	  a	  Shimadzu	  LCMS	  with	  an	  electro-­‐spray	  probe	  and	  samples	  were	  prepared	  as	  solutions	  of	  methanol	  unless	   otherwise	   stated.	  Melting	   points	  were	   obtained	   using	   Stuart	   Scientific	  Melting	  Point	  SMP	  1	  apparatus.	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3.1 	  -­‐	  Synthesis	  of	  Benzoyl-­‐O-­‐dihydroquinidine	  (76).37	  
	  In	   a	   dry	   100	   mL	   round-­‐bottomed	   flask	   was	   added	   129	   (2.37	   g,	   7.26	   mmol)	   and	  triethylamine	   (8.16	   ml,	   58.1	   mmol)	   in	   dichloromethane	   (36.3	   ml)	   at	   0	   °C	   to	   give	   a	  colourless	   solution.	   Benzoyl	   chloride	   (0.670	   ml,	   7.41	   mmol)	   was	   added	   slowly	   via	   a	  dropping	  funnel	  over	  a	  period	  of	  ten	  min.	  The	  solution	  was	  left	  to	  stir	  for	  1	  h.	  Water	  (20	  ml)	  was	  added	  to	   the	  solution	  and	   the	  organic	   layer	  was	  separated.	  The	  organic	   layer	  was	  then	  washed	  with	  5%	  sodium	  hydrogencarbonate	  solution	  (20	  ml)	  and	  then	  water	  (20	  ml).	  The	  solvent	  was	   removed	   in	   vacuo	   to	  yield	  an	  off-­‐white	   solid	   foam.	  This	  was	  recrystalised	   from	   the	  minimum	   amount	   of	  warm	  methanol	   to	   yield	  76	   (2.94	   g,	   6.83	  mmol,	  94	  %	  yield)	  as	  thick	  colourless	  crystals.	  1H	  NMR	  (400MHz,	  CDCl3):	  δ	  8.69	  (d,	  1H,	  ArH,	  J	  =	  4.51	  Hz),	  8.08	  (d,	  2H,	  ArH,	  2J	  =	  8.10	  Hz),	  7.99	  (d,	  1H,	  ArH,	  J	  =	  9.22	  Hz),	  7.53	  (d,	  2H,	  ArH,	  J	  =	  3.54	  Hz),	  7.45-­‐7.40	  (m,	  3H,	  ArH),	  7.34	  (dd,	  1H,	  ArH,	  J	  =	  9.15	  Hz,	  J	  =	  2.08	  Hz),	  6.82	  (d,	  1H,	  COOCH,	  J	  =	  6.67	  Hz),	  3.95	  (s,	  3H,	  OCH3),	  3.40	  (q,	  1H,	  COOCHCHN(CH2)2,	  J	  =	  8.00	  Hz),	  2.98-­‐2.71	   (m,	  4H,	  CHN(CH2)2),	   	  1.93	   (t,	  1H,	  alkyl,	   J	  =	  11.16	  Hz),	   	  1.72	   (s,	  1H,	  alkyl),	  1.61-­‐1.38	  (m,	  6H,	  alkyl),	  	  0.86	  (t,	  3H,	  CH2CH3,	  J	  =	  6.32	  Hz)	  
3.2 	  -­‐	  Synthesis	  of	  para-­‐Chlorobenzoyl-­‐O-­‐dihydroquinidine	  (78).37	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colourless	   solution.	   para-­‐chlorobenzoyl	   chloride	   (0.670	   ml,	   7.41	   mmol)	   was	   added	  slowly	  via	  a	  dropping	  funnel	  over	  a	  period	  of	  ten	  min.	  The	  solution	  was	  left	  to	  stir	  for	  1h.	  Water	   (20	   ml)	   was	   added	   to	   the	   solution	   and	   the	   organic	   layer	   was	   separated.	   The	  organic	   layer	  was	   then	  washed	  with	   5%	   sodium	  hydrogencarbonate	   solution	   (20	  ml)	  and	   then	  water	   (20	  ml).	  The	  solvent	  was	  removed	   in	  vacuo	   to	  yield	  an	  off-­‐white	  solid	  foam.	  This	  was	  recrystalised	  from	  the	  minimum	  amount	  of	  warm	  methanol	  to	  yield	  78	  	  (2.94	  g,	  6.83	  mmol,	  94	  %)	  as	  thick	  colourless	  crystals.	  1H	  NMR	  (400MHz,	  CDCl3):	  δ	  8.65	  (d,	  1H,	  ArH,	  J	  =	  4.54	  Hz),	  7.95	  (dq,	  3H,	  ArH,	  J	  =	  8.78	  Hz,	  J	  =	  2.11	  Hz),	  7.41-­‐7.29	  (m,	  5H,	  ArH),	   6.65	   (d,	   1H,	   COOCH,	   J	   =	   7.36	   Hz),	   3.90	   (s,	   3H,	   OCH3),	   3.34	   (q,	   1H,	  COOCHCHN(CH2)2,	   J	   =	   8.00	   Hz),	   2.88-­‐2.61	   (m,	   4H,	   CHN(CH2)2),	   1.80	   (t,	   1H,	   alkyl,	   J	   =	  11.20	  Hz),	  1.69-­‐1.65	  (m,	  2,	  alkyl),	  1.55-­‐1.40	  (m,	  6H,	  alkyl),	  	  0.83	  (t,	  3H,	  CH2CH3,	  J	  =	  7.15	  Hz).	   13C	   NMR	   (400MHz,	   CDCl3):	   δ	   165.03,	   158.12,	   147.65,	   143.93,	   132.05,	   131.20,	  129.13,	   128.40,	   122.09,	   118.81,	   101.57,	   77.22	   (t,	   CDCl3),	   59.66,	   55.780,	   51.02,	   50.14,	  37.55,	  27.38,	  26.32,	  25.65,	  23.85,	  12.12.	  LC-­‐MS (EI)+ m/z 487.1 (M+Na+)	  
3.3 	  -­‐	  Synthesis	  of	  1,2-­‐(bis-­‐O-­‐dihydroquinidinyl)	  Phthalate	  (72).37	  





























DCM, 0 °C →  20 °C, 1 h
51	  	  
(dd,	  2H,	  ArH,	  J	  =	  5.71	  Hz,	  J	  =	  3.33	  Hz),	  7.46-­‐7.44	  (m,	  2H,	  ArH),	  7.34	  (td,	  4H,	  ArH,	  J	  =	  7.21	  Hz,	   J	   =	   2.59	   Hz),	   6.65-­‐6.58	   (m,	   2H,	   COOCH),	   3.92	   (s,	   6H,	   OCH3),	   2.61	   (q,	   2H,	  COOCHCHN(CH2)2,	  J	  =	  8.00	  Hz),	  2.73-­‐2.54	  (m,	  8H,	  CHN(CH2)2),	  3.21-­‐3.18	  (m,	  2H,	  alkyl),	  1.48-­‐1.20	  (m,	  14H,	  alkyl),	  0.75	  (t,	  3H,	  CH2CH3,	  J	  =	  6.90Hz).	  13C	  NMR	  (300MHz,	  CDCl3):	  δ	  195.07,	  185.66,	  185.12,	  166.30,	  157.98,	  147.59,	  144.90,	  131.93,	  131.61,	  128.92,	  127.40,	  122.135,	  115.98,	  59.94,	  55.70,	  50.80,	  49.97,	  37.44,	  27.34,	  26.23,	  25.51,	  12.05,	  5.39;	  MS 
(EI)+ 	  m/z	  779.9	  (M+H+)	  
3.4 	  -­‐	  Synthesis	  of	  bis-­‐O-­‐Dihydroquinidinylphthalazine	  (68).37	  























a.) 1.5 eq. K2CO3





a.) tol, Δ, 2 h




was	  then	  recrystalised	  from	  the	  minimum	  amount	  of	  warm	  methanol	  to	  yield	  pure	  68	  (3.67	  g,	  4.72	  mmol,	  61	  %	  yield)	  as	  white	  crystals.	  1H	  NMR	  (400MHz,	  CDCl3):	  δ	  8.63	  (d,	  2H,	  ArH,	  J	  =	  4.53	  Hz),	  8.31	  (dd,	  2H,	  ArH,	  J	  =	  6.15	  Hz,	  J	  =	  3.26	  Hz),	  7.98	  (d,	  2H,	  ArH,	  J	  =	  9.21	  Hz),	  7.92	  (dd,	  2H,	  ArH,	  J	  =	  6.11	  Hz,	  J	  =	  3.29	  Hz),	  7.55	  (d,	  2H,	  ArH,	  J	  =	  2.66),	  7.43	  (d,	  2H,	  ArH,	  J	  =	  4.57	  Hz),	  7.35	  (dd,	  2H,	  ArH,	  J	  =	  9.21,	  J	  =	  2.68),	  6.97	  (d,	  2H,	  COOCH,	  J	  =	  6.35	  Hz),	  3.89	  (s,	  6H,	  OCH3),	  2.76-­‐2.67	  (m,	  8H,	  CHN(CH2)2,	  2.00-­‐1.92	  (m,	  2H,	  alkyl)	  1.69	  (m,	  2H,	  alkyl),	   156-­‐1.37	   (m,	   12H,	   alkyl),	   0.79	   (t,	   6H,	   CH2CH3,	   J	   =	   7.20Hz).	   13C	   NMR	   (400MHz,	  CDCl3):	   δ	   186.09,	   157.80,	   147.55,	   145.21,	   144.86,	   132.34,	   131.71,	   127.57,	   123.01,	  122.65,	   122.05,	   118.74,	   102.29,	   60.44,	   55.85,	   51.06,	   50.17,	   37.64,	   27.50,	   26.50,	   25.53,	  23.69,	  12.09.	  MS (EI)+ m/z 779.6 (M+H+)	  
3.5 	  -­‐	   Synthesis	   of	   para-­‐Chlorobenzoyl-­‐O-­‐(N-­‐fluorodihydroquinidine	  
tetrafluoroborate)	  (98).38	  





























ArH,	  J	  =	  9.24	  Hz),	  7.88	  (d,	  1H,	  ArH,	  J	  =	  4.53	  Hz),	  7.70	  (d,	  1H,	  ArH,	  J	  =	  8.62	  Hz),	  7.62	  (s,	  1H,	  ArH),	  7.53	  (dd,	  1H,	  ArH,	  J	  =	  9.25	  Hz,	  J	  =	  2.60	  Hz),	  7.41	  (d,	  1H,	  COOCH,	  J	  =	  2.53	  Hz),	  5.25	  (t,	  1H,	  J	  =	  0.39	  Hz),	  4.77-­‐4.68	  (m,	  3H),	  4.50	  (t,	  1H,	  J	  =	  0.37	  Hz),	  4.06	  (s,	  3H,	  OCH3),	  3.40	  (t,	  1H,	  J	  =	  7.20	  Hz),	  2.90-­‐2.87	  (m,	  3H),	  2.53	  (t,	  1H,	  J	  =	  8.40	  Hz),	  1.95	  (quin,	  2H,	  CH2CH3,	  J	  =	  7.53	  Hz),	  0.98	  (t,	  3H,	  CH2CH3,	  J	  =	  7.41	  Hz.	  19F	  NMR	  (270	  MHz,	  CD3CN):	  δ	  37.41	  (1F,	  [N-­‐
F]+),	  -­‐151.27	  (4F,	  BF4-­‐)	  MS (EI)+ m/z 483.1 (M - BF4-).	  
3.6 	  -­‐	  Synthesis	  of	  1-­‐Butyl-­‐3-­‐methylimidazolium	  chloride	  (87).39	  
	  In	   a	  500	  mL	   round-­‐bottomed	   flask	   fitted	  with	  a	   reflux	   condenser	  was	  121	   (22.82	  ml,	  286	   mmol)	   and	   87	   (27.0	   ml,	   372	   mmol)	   in	   acetonitrile	   (15.5	   ml)	   to	   give	   a	   yellow	  solution.	   The	   solution	  was	   brought	   to	   a	   gentle	   reflux	   and	   left	   to	   reflux	   for	   48	   h.	   The	  reaction	   solution	   was	   allowed	   to	   cool	   to	   room	   temperature	   and	   the	   solvent	   was	  removed	  in	  vacuo.	  The	  resultant	  pale	  yellow	  oil	  was	  re-­‐dissolved	  in	  dry	  acetonitrile	  (40	  ml)	  and	  added	  drop	  wise	  via	  a	  cannula	  to	  200	  ml	  dried	  ethyl	  acetate	  with	  stirring..	  The	  resultant	  solution	  was	  cooled	  to	  -­‐40°C	  for	  2	  h	  to	  yield	  87	  (49.7	  g,	  285	  mmol,	  99	  %)	  as	  very	  pale	  yellow	  crystals.	  1H	  NMR	  (300MHz,	  CDCl3):	  δ	  10.58	  (s,	  1H,	  NCHN),	  7.87	  (t,	  1H,	  N+CHCHN,	  J	  =	  1.70	  Hz),	  7.81	  (t,	  1H,	  N+CHCHN,	  J	  =	  1.66	  Hz),	  4.03	  (t,	  2H,	  NCH2,	  J	  =	  7.24	  Hz)	  4.01	  (s,	  3H,	  NCH3),	  1.82	  (quin,	  2H,	  NCH2CH2,	  J	  =	  7.20	  Hz),	  1.25	  (hex,	  2H,	  NCH2CH2CH2,	  J	  =	  7.59	  Hz),	  0.84	  (t,	  3H,	  NCH2CH2CH2CH3,	  J	  =	  7.36	  Hz)	  	  
3.7 	  -­‐	   Synthesis	  of	  1-­‐Butyl-­‐3-­‐methylimidazolium	  hexafluorophosphate	  
(80).39	  





















mixture	  was	   stirred	   at	   room	   temperature	   for	   2	   h	   affording	   a	   two-­‐phase	   system.	   The	  organic	   phase	   is	   washed	   with	   water	   (3	   x	   20	   ml),	   dichloromethane	   (40	   ml)	   and	  anhydrous	  magnesium	   sulfate	   (20	   g)	  were	   added.	   After	   an	   hour,	   the	   suspension	  was	  filtered	  and	  the	  volatile	  material	  was	  removed	   in	  vacuo	  to	  yield	  80	  (44.3	  g,	  156	  mmol,	  67	  %)	  as	  a	   light	  yellow	  viscous	  liquid,	  mp	  10	  °C,	  1H	  NMR	  (300MHz,	  CD3OD):	  δ	  8.73	  (s,	  1H,	  NCHN),	  7.53	  (t,	  1H,	  MeNCHCHNBu,	  J	  =	  1.74	  Hz)	  7.47	  (t,	  1H,	  MeNCHCHNBu,	  J	  =	  1.68	  Hz),	  4.15	  (t,	  2H,	  NCH2,	  J	  =	  7.34	  Hz),	  3.87	  (s,	  3H,	  NCH3),	  1.82	  (quintet,	  2H,	  NCH2CH2,	  J	  =	  7.61	  Hz),	  1.33	  (sextet,	  2H,	  NCH2CH2CH2,	   J	  =	  7.54	  Hz),	  0.94	  (t,	  3H,	  NCH2CH2CH2CH3,	   J	  =	  7.37	  Hz),	  13C	  NMR	  (400MHz,	  CD3OD):	  δ	  136.30,	  123.40,	  122.10,	  48.96,	  44.7	  (dt,	  CD3OD)	  34.78,	  31.38,	  18.78,	  12.04.	  
3.8 	  -­‐	  Synthesis	  of	  Sodium	  Dimalatoborate	  (88).40	  
	  In	   a	   100	  mL	   round-­‐bottomed	   flask	  was	  L-­‐(-­‐)-­‐Malic	   acid	   (5.36	   g,	   40.0	  mmol)	   in	  water	  (10.00	  ml)	  to	  give	  a	  colourless	  solution.	  Boric	  acid	  (1.237	  g,	  20	  mmol)	  was	  added	  and	  sodium	  hydroxide	  (0.800	  g,	  20.00	  mmol)	   in	  water	  (10.00	  ml)	  was	  added.	  The	  mixture	  was	  stirred	  and	  heated	  to	  100	  °C	  for	  3	  h	  until	  all	  water	  had	  evaporated	  to	  give	  88	  (5.84	  g,	  19.60	  mmol,	  98	  %)	  as	  a	  white	  crystalline	  solid.	  1H	  NMR	  (300MHz,	  acetone-­‐d6):	  δ	  4.34-­‐4.25	  (m,	  2H,	  CHCOOH),	  2.55-­‐2.51	  (m,	  2H,	  CHCOOH),	  2.26-­‐2.21	  (m,	  2H,	  BOOCCH)	  
3.9 	  -­‐	   Synthesis	   of	   1-­‐Butyl-­‐3-­‐methylimidazolium	   Dimalatoborate	  
(90).35	  
	   	  
HO O
OH 0.5 eq. NaOH
0.5 eq. B(OH)3





























87	  1.737	  g,	  9.94	  mmol)	  was	  dissolved	  in	  acetone	  (22.60	  ml)	  and	  treated	  with	  89	  (2.963	  g,	   9.94	   mmol)	   in	   acetone	   (22.60	   ml).	   The	   reaction	   mixture	   was	   stirred	   at	   room	  temperature	  overnight.	  During	  this	  period	  sodium	  chloride	  precipitated	  as	  a	  white	  solid.	  The	   reaction	  mixture	   was	   filtered	   and	   the	   solvent	   was	   removed	   in	   vacuo	   to	   give	  90	  (4.04	  g,	  9.75	  mmol,	  98	  %)	  as	  a	  very	  pale	  yellow,	  highly	  viscous	  oil.	   1H	  NMR	  (300MHz,	  CDCl3):	   δ	   9.11	   (s,	   1H,	   NCHN),	   7.65	   (t,	   1H,	   MeNCHCHNBu,	   J	   =	   1.72	   Hz),	   7.61	   (t,	   1H,	  MeNCHCHNBu,	  J	  =	  1.68	  Hz),	  4.40-­‐4.34	  (m,	  2H,	  CHCOOH),	  4.26	  (t,	  2H,	  NCH2,	  J	  =	  7.28	  Hz)	  3.94	   (s,	   3H,	   NCH3),	   2.59-­‐2.55	   (m,	   2H,	   CHCOOH),	   2.41-­‐2.34	   (m,	   2H,	   BOOCCH),	   1.80	  (quintet,	  2H,	  NCH2CH2,	  J	  =	  7.27	  Hz),	  1.27	  (sextet,	  2H,	  NCH2CH2CH2,	  J	  =	  7.75	  Hz),	  0.83	  (t,	  3H,	  NCH2CH2CH2CH3,	  J	  =	  8.17	  Hz).	  
3.10 -­‐	  Synthesis	  of	  Sodium	  Dimandelatoborate	  (89).40	  
	  In	  a	  100	  mL	  round-­‐bottomed	  flask	  was	  122	  (9.433	  g,	  62.0	  mmol)	  in	  water	  (15.50	  ml)	  to	  give	  a	  colourless	  solution.	  Boric	  acid	  (1.917	  g,	  31.0	  mmol)	  was	  added.	  Sodium	  hydroxide	  (1.240	  g,	  31.0	  mmol)	   in	  water	  (15.50	  ml)	  was	  added.	  The	  solution	  was	  then	  heated	  to	  100	  for	  2	  h	  and	  the	  water	  allowed	  to	  evaporate	  to	  yield	  89	  (10.25	  g,	  30.7	  mmol,	  99	  %)	  as	   a	  white	   crystalline	   solid	   1H	  NMR	   (300MHz,	   acetone-­‐d6):	   δ	   7.56-­‐7.47	   (m,	   2H,	   ArH),	  7.24-­‐7.14	  (m,	  3H,	  ArH),	  5.13-­‐5.04	  (m,	  1H,	  PhCH).	   































In	  a	  100	  mL	  round-­‐bottomed	  flask	  was	  87	  (2.327	  g,	  13.32	  mmol)	  in	  with	  stirring	  to	  give	  a	  white	  suspension.	  The	  suspension	  was	  filtered	  to	  remove	  all	  solids	  concentrated	  using	  a	  rotary	  evaporator	  to	  give	  91	  (5.87	  g,	  13.04	  mmol,	  98	  %)	  as	  a	  very	  pale	  yellow,	  highly	  viscous	  oil.	  [α]20D	  =	  123.8±0.2	  (c=0.39,	  CH3CN);	  1H	  NMR	  (300MHz,	  acetone-­‐d6):	  δ	  8.97	  (s,	  1H,	   NCHN),	   7.68-­‐7.60	   (m,	   4H,	   ArH),	   7.59	   (t,	   1H,	   N+CHCHN,	   J	   =	   1.57	   Hz),	   7.51	   (t,	   1H,	  N+CHCHN,	  J	  =	  1.75	  Hz),	  7.37-­‐7.23	  (m,	  6H,	  ArH),	  5.21	  (d,	  2H,	  PhCH,	  J	  =	  5.21	  Hz),	  4.15	  (t,	  2H,	  NCH2,	   J	  =	  7.34	  Hz),	  3.83	  (s,	  3H,	  NCH3),	  1.76	  (quin,	  2H,	  NCH2CH2,	   J	  =	  7.50	  Hz),	  1.25	  (hex,	   2H,	   NCH2CH2CH2,	   J	   =	   7.49	  Hz),	   0.87	   (t,	   3H,	   NCH2CH2CH2CH3,	   J	   =	   7.35);	   13C	  NMR	  (300MHz,	   CDCl3)	   δ	   178.28,	   178.16,	   139.80,	   139.76,	   135.26,	   128.25,	   128.13,	   127.65,	  127.47,	  126.17,	  126.04,	  123.26,	  121.83,	  78.00,	  77.88,	  49.56,	  35.94,	  31.72,	  19.16,	  13.30.	  
3.12 -­‐	   Synthesis	  of	   (3R,	   3aR,	   6S,	   6aS)-­‐3-­‐(Acetoxy)hexahydrofuro[3,2-­‐
b]furan-­‐6-­‐ol	  (93).42	  
	  100	  mL	  round-­‐bottomed	  flask	  was	  added	  Isosorbide	  (7	  g,	  47.9	  mmol),	  acetic	  anhydride	  (5.88	  ml,	  62.3	  mmol),	  and	  lead	  (II)	  oxide	  (0.267	  g,	  1.197	  mmol)	  in	  DCM	  (10	  ml)	  to	  give	  a	  colorless	   solution.	   The	   solution	   was	   stirred	   for	   24	   h.	   TLC	   (5%	  MeOH	   :	   95%	   CH2Cl2)	  showed	   only	   trace	   starting	   materials	   remained.	   Solvent	   was	   removed	   in	   vacuo	   and	  residual	  acetic	  anhydride	  and	  acetic	  acid	  by-­‐product	  was	  removed	  under	  high	  vacuum	  (8	  mbar)	  with	  mild	  heating	  to	  afford	  a	  yellow	  oil.	  The	  crude	  material	  was	  purified	  on	  a	  chromatography	  column	  (5%	  MeOH	  :	  95%	  DCM)	  to	  afford	  93	  (2.2	  g,	  11.69	  mmol,	  27.5	  %	  yield)	  as	  a	  viscous,	  colourless	  oil.	  1H	  NMR	  (300MHz,	  CDCl3):	  δ	  5.13	  (quin,	  1H,	  J	  =	  5.66	  Hz,	  4.83	  (q,	  1H,	   J	  =	  4.50	  Hz),	  4.30	  (t,	  1H,	   J	  =	  4.62	  Hz),	  3.95-­‐3.87	  (m,	  3H),	  3.78-­‐3.72	  (m,	  1H),	  2.17	  (q,	  1H,	  J	  =	  1.36	  Hz),	  2.13-­‐2.11	  (m,	  3H,	  COOCH3).	  13C	  NMR	  (CDCl3,	  300	  MHz):	  δ	  185.55,	  88.37,	  80.52,	  77,22	  (t,	  CD3Cl),	  76.44,	  75.77,	  74.29,	  70.36,	  20.90	  LC-­‐MS	  (EI)+	  m/z 















3.13 -­‐	   Synthesis	  of	   (3R,	   3aR,	   6S,	   6aS)-­‐3-­‐(Acetoxy)hexahydrofuro[3,2-­‐
b]furan-­‐6-­‐yl	  trifluoromethanesulfonate.	  (94).41	  
	  In	   a	  50	  mL	   round-­‐bottomed	   flask	  was	  93	   (827	  mg,	  4.39	  mmol)	   and	  pyridine	   (391	  µl,	  4.83	  mmol)	   in	   dichloromethane	   (1.03E+04	  µl)	   to	   give	   a	   yellow	   solution.	   The	   solution	  was	  cooled	  to	  0	  °C	  and	  stirred	  rapidly	  for	  30	  min.	  Trifluoromethanesulfonic	  anhydride	  (780	  µl,	  4.61	  mmol)	  was	  added	  carefully.	  After	  half	  an	  hour,	  the	  solution	  was	  allowed	  to	  warm	  to	  room	  temperature	  and	  stirred	  for	  a	  further	  2	  h.	  The	  solution	  was	  washed	  with	  water	  (30	  ml),	  5	  M	  HCl	  solution	  (30	  ml)	  and	  saturated	  sodium	  chloride	  solution	  (30	  ml).	  The	  organic	  phase	  was	  collected,	  dried	  with	  MgSO4	  and	  solvent	  was	  removed	  in	  vacuo	  to	  give	  94	  (1.2	  g,	  3.75	  mmol,	  85	  %	  yield)	  as	  an	  orange	  oil.	  1H	  NMR	  (300MHz,	  CDCl3):	  δ	  5.25	  (t,	  1H,	  J	  =	  2.85	  Hz),	  5.12	  (q,	  1H,	  J	  =	  5.45	  Hz),	  4.89	  (t,	  1H,	  J	  =	  5.09	  Hz),	  4.60	  (d,	  1H,	  J	  =	  4.70	  Hz),	  4.14	  (d,	  1H,	  J	  =	  11.94	  Hz),	  3.98-­‐3.90	  (m,	  2H),	  3.73	  (dd,	  1H,	  J	  =	  10.03	  Hz,	  J	  =	  5.01	  Hz),	   2.04	   (s,	   3H,	   COOCH3).	   13C	   NMR	   (CDCl3,	   300	  MHz):	   δ	   170.17,	   89.31,	   85.36,	   80.80,	  77.01	  (t,	  CD3Cl),	  73.35,	  72.71,	  70.65,	  20.35.	  MS	  (EI)+	  m/z	  321.00	  [M+H]+. 	  
3.14 -­‐	  Synthesis	  of	  2-­‐tert-­‐Butoxynitrobenzene	  (131)	  



















a.) 1.05 eq. KH / 1 HMDS
b.) 1.0 eq. tBuOH
a.) THF, 16 h 
b.) THF,  0 °C 





magnetic	  stir	  bar.	  tert-­‐Butanol	  (3.2	  ml,	  33.5	  mmol)	  was	  added	  and	  the	  solution	  cooled	  to	  0°C	  and	  the	  reaction	  was	  stirred.	  The	  hexamethyldisilazane	  solution	  was	  slowly	  added	  via	  a	  cannula,	  allowed	  to	  warm	  to	  RT	  and	  stirred	  for	  16	  h.	  The	  resulting	  Dark	  yellow	  oil	  was	   diluted	   with	   30ml	   ethyl	   acetate	   and	   washed	   with	   ammonium	   chloride	   (50ml),	  water	  (2x50ml)	  and	  brine	  (50ml).	  All	  aqueous	  washings	  were	  then	  back-­‐extracted	  with	  ethyl	   acetate	   (50ml).	   All	   organic	   fractions	   were	   then	   combined	   and	   dried	   over	  magnesium	  sulfate	  and	  all	  solvent	  removed	  under	  reduced	  pressure	  to	  yield	  130 (5.88	  g,	  30.1	  mmol,	  90	  %)	  as	  a	  dark	  brown	  oil.	  1H	  NMR	  (400MHz,	  CDCl3):	  δ	  7.69	  (d,	  1H,	  ArH,	  J	  =	  8.07	  Hz),	  7.44	  (dd,	  1H,	  ArH,	  J	  =	  8.37	  Hz,	  J	  =	  7.41	  Hz),	  7.20	  (d,	  1H,	  ArH,	  J	  =	  8.37	  Hz),	  1.39	  (s,	  9H,	  OC(CH3)3)	  
3.15 -­‐	  Synthesis	  of	  2-­‐tert-­‐Butoxyaniline	  (132)	  









3.16 -­‐	   Synthesis	   of	   (E)-­‐2-­‐Butoxy-­‐N-­‐(4-­‐nitrobenzylidene)phenylamine	  
(107)	  
	  In	  a	  100	  ml	  round-­‐bottomed	  flask	  was	  132	  (915	  mg,	  6.05	  mmol)	  and	  2-­‐butoxyaniline	  (1	  g,	  6.05	  mmol)	   in	  dichloromethane	  (20	  ml)	   to	  give	  a	  brown	  solution.	  The	  reaction	  was	  stirred	  with	  a	  magnetic	  stir	  bar	  for	  10	  min.	  Anhydrous	  magnesium	  sulphate	  (1	  g)	  was	  added	  and	  the	  solution	  was	  briefly	  stirred	  to	  mix	  and	  then	  the	  solution	  was	  left	  to	  stand	  for	  16	  h	  under	  nitrogen.	  The	  resultant	  orange	  solution	  was	  filtered	  and	  concentrated	  in	  
vacuo	  to	  yield	  107	  	  (1.408	  g,	  4.72	  mmol,	  78	  %	  yield)	  as	  a	  crystalline	  pale	  brown	  solid.	  1H	  NMR	  (400MHz,	  CDCl3):	  δ	  8.55	  (s,	  1H,	  N=CH),	  8.30	  (d,	  2H,	  o-­‐NO2-­‐ArH,	  J	  =	  8.32	  Hz),	  8.05	  (d,	  2H,	  m-­‐NO2-­‐ArH,	  J	  =	  8.11	  Hz),	  7.13-­‐7.07	  (m,	  4H,	  ArH),	  1.30	  (s,	  9H,	  OC(CH3)).	  
3.17 -­‐	  Synthesis	  of	  (E)-­‐4-­‐Methoxy-­‐N-­‐benzylidenephenylamine	  (109)	  






























90	  %	  yield)	  as	  a	  crystalline	  pale	  brown	  solid.	   1H	  NMR	  (400MHz,	  CDCl3):	  δ	  8.48	  (s,	  1H,	  N=CH),	  7.91-­‐7.88	  (m,	  2H,	  ArH,)	  7.46	  (t,	  3H,	  ArH,	  J	  =	  3.22	  Hz),	  7.24	  (d,	  2H,	  m-­‐MeO-­‐ArH,	  J	  =	  9.01	  Hz),	  6.94	  (d,	  2H,	  m-­‐MeO-­‐ArH,	  J	  =	  8.98	  Hz),	  3.83	  (s,	  3H,	  OCH3).	  
3.18 Synthesis	   of	   (E)-­‐4-­‐Methoxy-­‐N-­‐(2-­‐pyridinylidene)phenylamine	  
(111)	  
	  In	  a	  100	  mL	  round-­‐bottomed	  flask	  was	  added	  136	  (8.43	  ml,	  83	  mmol)	  and	  135	  (10.24	  g,	  83	  mmol)	  in	  dichloromethane	  (40	  ml)	  to	  give	  a	  brown	  solution.	  10	  g	  dried	  magnesium	  sulphate	  was	  added	  and	  the	  solution	  was	  briefly	  stirred	  to	  mix	  and	  then	  left	  to	  stand	  for	  16	  h.	  The	  solution	  was	  filtered	  to	  remove	  magnesium	  sulphate	  and	  the	  solvent	  removed	  in	   vacuo	   to	   yield	   111	   (13.11	   g,	   62.1	   mmol,	   74.6	  %	   yield)	   as	   a	   brown	   solid	   1H	   NMR	  (400MHz,	   CDCl3):	   δ	   8.68	   (dd,	   1H,	  o-­‐pyridinyl-­‐H,	   J	   =	   4.86	  Hz,	   J	   =	   1.60	  Hz),	   8.62	   (s,	   1H,	  N=CH),	  8.17	  (d,	  1H,	  m-­‐pyridinyl-­‐H,	  J	  =	  7.95	  Hz),	  7.78	  (t,	  1H,	  m-­‐pyridinyl-­‐H,	  J	  =	  7.50	  Hz),	  7.33	  (dt,	  3H,	  m-­‐pyridinyl-­‐H,	  m-­‐OMe-­‐ArH,	   J	  =	  6.58	  Hz,	   J	  =	  2.75	  Hz),	  6.94	  (d,	  2H,	  o-­‐OMe-­‐ArH,	  J	  =	  8.90	  Hz),	  3.82	  (s,	  3H,	  OCH3).	  



































In	   a	   dry	   10	   mL	   round-­‐bottomed	   flask	   was	   added	   107	   (80	   mg,	   0.268	   mmol)	   and	  N-­‐fluoropyridinium	   Trifluoromethanesulfonate	   (6.63	   mg,	   0.027	   mmol)	   in	   dry	  dichloromethane	  (3	  ml)	  under	  an	  atmosphere	  of	  nitrogen	  to	  give	  a	  dark	  yellow	  solution,	  which	  was	  stirred	   for	  5	  min.	  Ethyl	  diazoacetate	   (32.7	  µl,	  0.268	  mmol)	  was	  added	  and	  the	  reaction	  was	  stirred	  for	  12	  h,	  during	  which	  time	  nitrogen	  bubbles	  could	  be	  observed	  evolving	   from	   the	   solution.	   The	   solution	  was	   filtered	   through	   a	   plug	   of	   celite	   and	   the	  solvent	   was	   removed	   in	   vacuo.	   Purification	   via	   flash	   chromatography	   with	   diethyl	  ether/	   petroleum	   ether	   (20:80)	   yielded	   108	   (46	   mg,	   0.120	   mmol,	   44.6%),1H	   NMR	  (300MHz,	  CDCl3):	  δ	  8.20	  (d,	  2H,	  o-­‐NO2ArH,	  J	  =	  8.86	  Hz),	  7.73	  (d,	  2H,	  m-­‐NO2ArH,	  J	  =	  8.81	  Hz),	  7.03-­‐6.95	  (m,	  4H,	  MeOArH),	  4.03	  (dd,	  2H,	  COOCH2,	   J	  =	  9.47,	   J	  =	  7.17),	  3.58	  (d,	  1H,	  CHCOOEt,	  J	  =	  6.64	  Hz),	  3.19	  (d,	  1H,	  CHPhNO2,	  J	  =	  6.65	  Hz),	  1.32	  (s,	  9H,	  O(CH3)),	  1.08,	  (t,	  3H,	  COOCH2CH3,	   J	  =	  7.14	  Hz);	  13C	  NMR	  (CDCl3,	  300	  MHz):	  δ	  166.8,	  155.9,	  147.8,	  144.1,	  140.9,	  127.6,	  123.7,	  120.6,	  114.4,	  61.5,	  55.3,	  46.6,	  45.1,	  13.9	  





















	  In	  a	  dry	  25	  mL	  round-­‐bottomed	  flask	  was	  111	   	   (145	  mg,	  0.565	  mmol)	  and	  Selectfluor	  (20	  mg,	  0.056	  mmol)	  in	  acetonitrile	  (2.17	  ml)	  under	  an	  atmosphere	  of	  nitrogen	  to	  give	  a	  yellow	  solution,	  which	  was	  stirred	  for	  5	  min.	  Ethyl	  diazoacetate	  (69.8	  µl,	  0.565	  mmol)	  was	  added	  and	   the	  reaction	  was	  stirred	   for	  12	  h,	  during	  which	   time	  nitrogen	  bubbles	  could	  be	  observed	  evolving	  from	  the	  solution.	  The	  solution	  was	  filtered	  through	  a	  plug	  of	  celite	  and	  the	  solvent	  was	  removed	   in	  vacuo.	  Purification	  via	   flash	  chromatography	  with	  diethyl	  ether/	  petroleum	  ether	  (40:60)	  yielded	  112	  (141	  mg,	  0.412	  mmol,	  73	  %).;	  	  1H	  NMR	  (300MHz,	  CDCl3):	  δ	  8.21	  (d,	  2H,	  o-­‐O2NArH,	  J	  =	  8.87	  Hz),	  7.69	  (d,	  2H,	  m-­‐O2NArH,	  J	  =	  8.53	  Hz),	  6.97	   (d,	  2H,	  m-­‐MeOArH,	   J	  =	  8.98	  Hz),	  6.83	   (d,	  2H,	  o-­‐MeOArH,	   J	  =	  8.99	  Hz),	  4.02	  (dd,	  2H,	  COOCH2,	  J	  =	  9.00	  Hz,	  J	  =	  7.14	  Hz),	  3.77	  (s,	  3H,	  OCH3),	  3.57	  (d,	  1H,	  CHCOOEt,	  
J	  =	  6.78	  Hz),	  3.21	  (d,	  1H,	  CHPh,	   J	  =	  6.76	  Hz),	  1.04	  (t,	  3H,	  COOCH2CH3,	   J	  =	  7.13	  Hz).	   13C	  NMR	  (CDCl3,	  300	  MHz):	  δ	  167.4,	  156.2,	  149.5,	  149.2,	  145.2,	  135.5,	  122.9,	  120.7,	  114.5,	  61.1,	  55.4,	  45.5,	  45.0,	  13.8;	  MS	  (EI)+:	  m/z	  597	  (100%)	  
	  
Into a 12 Reaction carrousel were placed seven carousel tubes and each was charged with an	  


































Tube 1: 69 (10 mol %) + 97 (10 mol %)
Tube 2: 72 (10 mol %) + 97 (10 mol %)
Tube 3: 73 (10 mol %) + 97 (10 mol %)
Tube 4: 74 (10 mol %) + 97 (10 mol %)
Tube 5: 75 (10 mol %) + 97 (10 mol %)
Tube 6: 76 (10 mol %) + 97 (10 mol %)
Tube 7: 78 (10 mol %) + 97 (10 mol %)
107 Cis-Rac 108
63	  	  
0.027	  mmol;	  78,	  13.1	  mg,	  0.027	  mmol)	  and	  97,	  19	  mg,	  0.054	  mmol	  in	  acetonitrile	  (1	  ml)	  to	  give	  a	  colourless	  solution	  and	  was	  stirred	  for	  30	  min.	  107	  (80	  mg,	  0.268	  mmol)	  was	  added	  to	  each	  solution,	  the	  solution	  was	  stirred	  for	  a	  further	  15	  min.	  Ethyl	  diazoacetate	  (32.7	   µl,	   0.268	  mmol)	  was	   added	   to	   each	   tube	   and	   the	   solution	  was	   stirred	   for	   48	   h.	  Each	   solution	   was	   filtered	   through	   a	   plug	   of	   celite	   and	   the	   solvent	   was	   removed	   in	  vacuo.	   Purification	   via	   flash	   chromatography	   with	   diethyl	   ether/	   petroleum	   ether	  (40:60)	  yielded	  108	  (Yields:	  Tube	  1	  =	  24	  mg,	  23	  %;	  Tube	  2:	  34	  mg,	  33	  %;	  Tube	  3	  =	  8	  mg,	  8	  %;	  Tube	  4:	  no	  yield;	  Tube	  5	  =	  19	  mg,	  18	  %;	  Tube	  6	  =	  13	  mg,	  13	  %;	  Tube	  7	  =	  21	  mg,	  20	  %).	  All	  tubes:	  α]20D	  =	  0	  (c=1.0,	  CH3Cl)	  
 
Into a 12 Reaction carrousel were placed seven carousel tubes and each was charged with an	  









Tube 1: 69 (10 mol %) + 97 (10 mol %)
Tube 2: 72 (10 mol %) + 97 (10 mol %)
Tube 3: 73 (10 mol %) + 97 (10 mol %)
Tube 4: 74 (10 mol %) + 97 (10 mol %)
Tube 5: 75 (10 mol %) + 97 (10 mol %)
Tube 6: 76 (10 mol %) + 97 (10 mol %)




Into a 12 Reaction carrousel were placed seven carousel tubes and each was charged with an	  
O-­‐protected	  alkaloid	  (tube	  1:	  69,	  21.8	  mg;	  tube	  2:	  72,	  22.0	  mg,	  0.027	  mmol;	  tube	  3:	  73,	  20.5	  mg,	  0.027	  mmol;	  74,	  22.1	  mg,	  0.027	  mmol;	  75,	  14.7	  mg,	  0.027	  mmol;	  76,	  12.1	  mg,	  0.027	  mmol;	  78,	  13.1	  mg,	  0.027	  mmol)	  and	  97,	  19	  mg,	  0.054	  mmol	  in	  acetonitrile	  (1	  ml)	  to	  give	  a	  colourless	  solution	  and	  was	  stirred	  for	  30	  min.	  111	  (80	  mg,	  0.268	  mmol)	  was	  added	  to	  each	  solution,	  the	  solution	  was	  stirred	  for	  a	  further	  15	  min.	  ethyl	  diazoacetate	  (32.7	   µl,	   0.268	  mmol)	  was	   added	   to	   each	   tube	   and	   the	   solution	  was	   stirred	   for	   48	   h.	  Each	   solution	   was	   filtered	   through	   a	   plug	   of	   celite	   and	   the	   solvent	   was	   removed	   in	  vacuo.	   Purification	   via	   flash	   chromatography	   with	   diethyl	   ether/	   petroleum	   ether	  (40:60)	  yielded	  112	  (Yields:	  Tube	  1	  =	  38	  mg,	  47	  %;	  Tube	  2:	  42	  mg,	  52	  %;	  Tube	  3	  =	  30	  mg,	  38	  %;	  Tube	  4:	  12	  mg,	  15	  %;	  Tube	  5	  =	  38	  mg,	  47	  %;	  Tube	  6	  =	  39	  mg,	  49	  %;	  Tube	  7	  =	  43	  mg,	  54	  %).	  All	  tubes:	  α]20D	  =	  0	  (c=1.0,	  CH3Cl)	  
3.20 - Ionic Liquid Mediated Aziridinations 
	  












Tube 1: 69 (10 mol %) + 97 (10 mol %)
Tube 2: 72 (10 mol %) + 97 (10 mol %)
Tube 3: 73 (10 mol %) + 97 (10 mol %)
Tube 4: 74 (10 mol %) + 97 (10 mol %)
Tube 5: 75 (10 mol %) + 97 (10 mol %)
Tube 6: 76 (10 mol %) + 97 (10 mol %)


















was	   added	   to	   each	   tube	   and	   the	   solutions	   were	   stirred	   for	   16	   h.	   Each	   solution	   was	  filtered	  through	  a	  plug	  of	  celite	  and	  the	  solvent	  was	  removed	  in	  vacuo.	  Purification	  via	  flash	  chromatography	  with	  diethyl	  ether/	  petroleum	  ether	  (40:60)	  yielded	  112	  (yields:	  Tube	  1	  =	  231	  mg,	  82	  %;	  Tube	  2	  =	  236	  mg,	  84	  %).	  	  	  
	  












91 + DCM (tube 1)





BINAP:	  	   	   Binapthalene	  
CIL:	  	   	   	   Chiral	  ionic	  liquid	  
13CNMR:	  	   	   Carbon-­‐13	  nuclear	  magnetic	  resonance	  (spectroscopy)	  
COD:	   	   	   Cyclooctadiene	  
DCM:	  	   	   	   Dichloromethane	  
DET:	  	   	   	   Diethyl	  Tartrate	  	  
DHQD:	  	   	   Dihydroquinidine	  
DIPAMP:	  	   	   Ethane-­‐1,2-­‐diylbis[(2-­‐methoxyphenyl)phenylphosphane	  
D.R.	  	   	   	   Diastereoisomeric	  ratio	  
EDA:	  	   	   	   Ethyl	  diazoacetate	  
e.e.	  	  	   	   	   Enantiomeric	  excess	  
19FNMR:	  	   	   Fluorine-­‐19	  nuclear	  magnetic	  resonance	  (spectroscopy)	  
FTIR:	  	   	   	   Fourier	  transform	  infrared	  (spectroscopy)	  
1H-­‐NMR:	  	   	   Proton	  nuclear	  magnetic	  resonance	  (spectroscopy)	  
HPLC:	  	  	   	   High	  performance	  liquid	  chromatography	  
IL:	  	   	   	   	   Ionic	  liquid	  
L-­‐DOPA:	  	  	   	   (S)-­‐2-­‐amino-­‐3-­‐(3,4-­‐dihydroxyphenyl)propanoic	  acid	  
MS:	  	   	   	   Mass	  spectrometry	  
ppm:	   	   	   Parts	  per	  million	  
SEAr:	  	   	   	   Electrophilic	  aromatic	  substitution	  
SN:	  	   	   	   	   Nucleophilic	  substitution	  
VAPOL:	  	   	   Vaulted biphenanthrol	   	  
ii	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